<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84782</article-id><article-id pub-id-type="doi">10.7554/eLife.84782</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Melanocortin 1 receptor regulates cholesterol and bile acid metabolism in the liver</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-298655"><name><surname>Thapa</surname><given-names>Keshav</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-298656"><name><surname>Kadiri</surname><given-names>James J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-298657"><name><surname>Saukkonen</surname><given-names>Karla</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8767-2074</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-298658"><name><surname>Pennanen</surname><given-names>Iida</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-319753"><name><surname>Ghimire</surname><given-names>Bishwa</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-298659"><name><surname>Cai</surname><given-names>Minying</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-298660"><name><surname>Savontaus</surname><given-names>Eriika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-298123"><name><surname>Rinne</surname><given-names>Petteri</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6916-8627</contrib-id><email>pperin@utu.fi</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vghhr25</institution-id><institution>Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku</institution></institution-wrap><addr-line><named-content content-type="city">Turku</named-content></addr-line><country>Finland</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vghhr25</institution-id><institution>Drug Research Doctoral Programme (DRDP), University of Turku</institution></institution-wrap><addr-line><named-content content-type="city">Turku</named-content></addr-line><country>Finland</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040af2s02</institution-id><institution>Institute for Molecular Medicine Finland (FIMM), HiLIFE Helsinki Institute of Life Science, University of Helsinki</institution></institution-wrap><addr-line><named-content content-type="city">Helsinki</named-content></addr-line><country>Finland</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vghhr25</institution-id><institution>Faculty of Medicine, University of Turku</institution></institution-wrap><addr-line><named-content content-type="city">Turku</named-content></addr-line><country>Finland</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03m2x1q45</institution-id><institution>Department of Chemistry and Biochemistry, University of Arizona</institution></institution-wrap><addr-line><named-content content-type="city">Tucson</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vghhr25</institution-id><institution>Turku Center for Disease Modeling, University of Turku</institution></institution-wrap><addr-line><named-content content-type="city">Turku</named-content></addr-line><country>Finland</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dbzj528</institution-id><institution>Unit of Clinical Pharmacology, Turku University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Turku</named-content></addr-line><country>Finland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Quinn</surname><given-names>Matthew A</given-names></name><role>Reviewing Editor</role><aff><institution>Wake Forest School of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012mef835</institution-id><institution>Augusta University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>25</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84782</elocation-id><history><date date-type="received" iso-8601-date="2022-11-08"><day>08</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-07-13"><day>13</day><month>07</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-11-09"><day>09</day><month>11</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.11.08.515543"/></event></pub-history><permissions><copyright-statement>© 2023, Thapa et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Thapa et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84782-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84782-figures-v1.pdf"/><abstract><p>Melanocortin 1 receptor (MC1-R) is widely expressed in melanocytes and leukocytes and is thus strongly implicated in the regulation of skin pigmentation and inflammation. MC1-R has also been found in the rat and human liver, but its functional role has remained elusive. We hypothesized that MC1-R is functionally active in the liver and involved in the regulation of cholesterol and bile acid metabolism. We generated hepatocyte-specific MC1-R knock-out (Mc1r LKO) mice and phenotyped the mouse model for lipid profiles, liver histology, and bile acid levels. Mc1r LKO mice had significantly increased liver weight, which was accompanied by elevated levels of total cholesterol and triglycerides in the liver as well as in the plasma. These mice demonstrated also enhanced liver fibrosis and a disturbance in bile acid metabolism as evidenced by markedly reduced bile acid levels in the plasma and feces. Mechanistically, using HepG2 cells as an in vitro model, we found that selective activation of MC1-R in HepG2 cells reduced cellular cholesterol content and enhanced uptake of low- and high-density lipoprotein particles <italic>via</italic> a cAMP-independent mechanism. In conclusion, the present results demonstrate that MC1-R signaling in hepatocytes regulates cholesterol and bile acid metabolism and its deficiency leads to hypercholesterolemia and enhanced lipid accumulation and fibrosis in the liver.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>melanocortin 1 receptor</kwd><kwd>cholesterol</kwd><kwd>triglyceride</kwd><kwd>fibrosis</kwd><kwd>steatosis</kwd><kwd>bile acid</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002341</institution-id><institution>Academy of Finland</institution></institution-wrap></funding-source><award-id>315351</award-id><principal-award-recipient><name><surname>Rinne</surname><given-names>Petteri</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006306</institution-id><institution>Sigrid Juséliuksen Säätiö</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rinne</surname><given-names>Petteri</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003125</institution-id><institution>Suomen Kulttuurirahasto</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rinne</surname><given-names>Petteri</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>The Finnish Foundation for Cardiovascular Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Savontaus</surname><given-names>Eriika</given-names></name><name><surname>Rinne</surname><given-names>Petteri</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM-104080</award-id><principal-award-recipient><name><surname>Cai</surname><given-names>Minying</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Melanocortin 1 receptor (MC1-R) deficiency in hepatocytes increases cholesterol levels in the circulation and liver in mice, while selective activation of MC1-R reduces cellular cholesterol content in cultured hepatocytes.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Obesity is recognized as a global epidemic and is a major risk factor for type 2 diabetes, dyslipidemia, and cardiovascular disease (<xref ref-type="bibr" rid="bib4">Caballero, 2007</xref>). In particular, visceral obesity is associated with atherogenic dyslipidemia characterized by high levels of triglycerides (TG), TG-rich lipoproteins, and low-density lipoprotein (LDL) cholesterol and reduced high-density lipoprotein (HDL) cholesterol in the blood (<xref ref-type="bibr" rid="bib20">Grundy, 2004</xref>; <xref ref-type="bibr" rid="bib26">Klop et al., 2013</xref>). The liver plays a central role in this pathogenetic process as a regulator of cholesterol and fatty acid metabolism. As a consequence of hepatic dysregulation, de novo production and storage of cholesterol and fatty acids are enhanced leading to lipid accumulation in the liver, which eventually manifests as non-alcoholic fatty liver disease (NAFLD) (<xref ref-type="bibr" rid="bib13">Diehl and Day, 2017</xref>; <xref ref-type="bibr" rid="bib16">Friedman et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Than and Newsome, 2015</xref>). Novel therapeutic strategies to enhance clearance and reduce excessive production of cholesterol and fatty acids in the liver are needed to mitigate the burden of obesity-associated dyslipidemia, NAFLD, and associated cardiovascular complications such as atherosclerosis.</p><p>Melanocortins are a family of peptide hormones that are proteolytically cleaved from the precursor molecule proopiomelanocortin (POMC) to yield adrenocorticotrophin (ACTH) and α-, β-, and γ-melanocyte stimulating hormone (α-, β-, and γ-MSH) (<xref ref-type="bibr" rid="bib17">Gantz and Fong, 2003</xref>; <xref ref-type="bibr" rid="bib58">Smith and Funder, 1988</xref>). Melanocortins bind to and activate five different G-protein coupled melanocortin receptor subtypes named from MC1-R to MC5-R (<xref ref-type="bibr" rid="bib17">Gantz and Fong, 2003</xref>). Melanocortins and their receptors are expressed in the brain as well as in the periphery and regulate important physiological functions including skin pigmentation, sexual behavior, immune responses, and energy homeostasis (<xref ref-type="bibr" rid="bib6">Catania et al., 1996</xref>; <xref ref-type="bibr" rid="bib64">Wikberg and Mutulis, 2008</xref>; <xref ref-type="bibr" rid="bib65">Yeo et al., 2021</xref>). There has been wide interest in melanocortin receptors as potential drug targets and in fact, melanocortin receptor-targeted drugs have been recently approved for the treatment of rare skin diseases and genetic obesity syndromes (<xref ref-type="bibr" rid="bib38">Montero-Melendez et al., 2022</xref>). MC1-R was the first member of the melanocortin receptor family to be cloned and it binds only α-MSH with high affinity (<xref ref-type="bibr" rid="bib40">Mountjoy, 1994</xref>; <xref ref-type="bibr" rid="bib39">Mountjoy et al., 1992</xref>). MC1-R is abundantly expressed in melanocytes in the skin and is thus implicated as an integral regulator of skin pigmentation. MC1-R expression has been also demonstrated on a variety of peripheral cells including monocytes, macrophages, dendritic cells, neutrophils, endothelial cells, and fibroblasts (<xref ref-type="bibr" rid="bib1">Becher et al., 1999</xref>; <xref ref-type="bibr" rid="bib6">Catania et al., 1996</xref>; <xref ref-type="bibr" rid="bib21">Hartmeyer et al., 1997</xref>; <xref ref-type="bibr" rid="bib48">Reichrath and Girndt, 2005</xref>). Accordingly, increasing evidence demonstrates that MC1-R mediates potent and wide-ranging anti-inflammatory actions by suppressing the production of pro-inflammatory cytokines while simultaneously increasing the production of anti-inflammatory cytokines (<xref ref-type="bibr" rid="bib7">Catania et al., 2004</xref>). Intriguingly, <italic>MC1R/Mc1r</italic> mRNA has also been detected in the human and rat liver following the testing of a hypothesis that MC-Rs might modulate inflammation in the liver (<xref ref-type="bibr" rid="bib18">Gatti et al., 2006</xref>; <xref ref-type="bibr" rid="bib34">Malik et al., 2012</xref>). However, these early studies aimed to only characterize the expression profile of different MC-Rs in the liver, and the functional role of hepatic MC1-R has thereby remained unexplored.</p><p>We have recently found that global deficiency of MC1-R signaling accelerates atherosclerosis in apolipoprotein E knockout mice (<italic>Apoe<sup>-/-</sup></italic>) by increasing arterial monocyte accumulation and by disturbing cholesterol and bile acid metabolism (<xref ref-type="bibr" rid="bib52">Rinne et al., 2018</xref>). Specifically, MC1-R deficient mice showed elevated cholesterol levels in the plasma and liver in conjunction with a distinct bile acid profile characterized by reduced primary and increased secondary bile acid levels. This phenotype could be, however, caused by multiple mechanisms leaving an open question of whether MC1-R in the liver has a regulatory role in cholesterol and bile acid metabolism. In the present study, we aimed to address this question by engineering a hepatocyte-specific MC1-R knock-out mouse model. We here show that the loss of MC1-R signaling in hepatocytes causes hypercholesterolemia and enhanced lipid accumulation in the liver, and disturbs bile acid metabolism. Moreover, using HepG2 cells as an in vitro model, we found that α-MSH and selective MC1-R activation reduced cellular cholesterol content and enhanced uptake of LDL and HDL. This study demonstrates that MC1-R is functionally active in the liver and regulates cholesterol and bile acid metabolism in a protective way that could also have therapeutic implications.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Hepatocyte-specific MC1-R deficiency enhances cholesterol and lipid accumulation in the liver</title><p>We first aimed to investigate whether MC1-R is expressed in the mouse liver. Immunohistochemical staining revealed a strong and uniform expression of MC1-R in the liver (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Immunofluorescence staining further revealed that MC1-R expression co-localizes with the hepatocyte marker serum albumin (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) as well as with the cholangiocyte marker cytokeratin 19 and the monocyte and macrophage marker Mac-2 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), while no clear colocalization was observed in CD31-positive endothelial cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Furthermore, we sought to investigate whether the expression level of MC1-R in the liver is affected by feeding mice a cholesterol-rich Western diet. Remarkably, 12 weeks of Western diet feeding resulted in significant downregulation of the MC1-R mRNA level in the liver (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This result was further corroborated by Western blotting, which showed reduced protein expression of MC1-R in the liver of Western diet-fed mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). The specificity of the MC1-R signal was validated by pre-adsorption of the antibody with an MC1-R blocking peptide (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> and <xref ref-type="supplementary-material" rid="fig1s2sdata1">Figure 1—figure supplement 2—source data 1</xref>). Furthermore, using RNA sequencing data from human liver biopsies (<xref ref-type="bibr" rid="bib19">Govaere et al., 2020</xref>), we found that hepatic <italic>MC1R</italic> expression was significantly downregulated (log2 fold change = −1.1) in patients with NAFLD or nonalcoholic steatohepatitis (NASH) compared to control cases (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Melanocortin 1 receptor (MC1-R) is expressed in the mouse liver and down-regulated in mice fed a cholesterol-rich diet.</title><p>(<bold>A</bold>) Immunostaining of MC1-R staining in the liver of chow-fed C57Bl/6 J mouse. In the control section, anti-MC1-R antibody was replaced by purified normal rabbit IgG (isotype control). Scale bar, 50 µm. (<bold>B</bold>) Immunofluorescence staining of MC1-R (red) and the hepatocyte marker serum albumin (green) in the liver of chow-fed C57Bl/6 J mouse. Scale bar, 20 μm. (<bold>C</bold>) Quantitative real-time polymerase chain reaction (qPCR) analysis of <italic>Mc1r</italic> mRNA expression in the liver of chow- and Western diet-fed mice. (<bold>D</bold>) Representative Western blots of MC1-R and β-actin (loading control) and quantification of MC1-R protein level in the liver of chow- and Western diet-fed mice. *p<italic>&lt;0.05</italic> and **p<italic>&lt;0.01</italic> versus chow-fed mice by Student’s t-test. (<bold>E</bold>) <italic>MC1R</italic> gene expression in human liver biopsies from control cases (n=10) and patients with nonalcoholic fatty liver disease (NAFLD, n=51) or nonalcoholic steatohepatitis (NASH, n=155). Violin plots show normalized log2 RPKM values (reads per kilobase of exon per million reads mapped) and medians (dashed line) for each sample group. (<bold>F</bold>) Schematic presentation of the loxP-flanked (floxed) <italic>Mc1r</italic> allele and the positions of forward and reverse primers used for PCR genotyping. PCR analysis of genomic DNA extracted from the liver of Alb-Cre-negative and -positive mice that were homozygous for the Mc1r floxed allele (<italic>Mc1r<sup>fl/fl</sup></italic>). The size of the recombined allele is ~217 bp. (<bold>G</bold>) qPCR analysis of <italic>Mc1r</italic> expression in the liver of chow-fed <italic>Mc1r<sup>fl/fl</sup></italic>, <italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>, and Mc1r LKO (<italic>Mc1r<sup>fl/fl</sup> Alb<sup>Cre/+</sup></italic>) mice at the age of 16 weeks. (<bold>H, I</bold>) Absolute liver weight and liver to body weight ratio (expressed as a percentage of body weight) in chow-fed <italic>Mc1r<sup>fl/fl</sup></italic>, <italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>, and Mc1r LKO mice at the age of 16 weeks. Values are mean ± SEM, n=5–10 mice per group in each graph. *p<italic>&lt;0.05</italic>, **p<italic>&lt;0.01,</italic> and ****p<italic>&lt;0.0001</italic> for the indicated comparisons by one-way ANOVA and Dunnet <italic>post hoc</italic> tests. Mc1r LKO, hepatocyte-specific MC1-R knock-out mice.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Immunofluorescence staining of melanocortin 1 receptor (MC1-R) in the mouse liver.</title><p>(<bold>A</bold>) Immunofluorescence staining of MC1-R (red) and the cholangiocyte marker cytokeratin 19 (CK19, green) in the liver of a chow-fed C57Bl/6 J mouse. (<bold>B</bold>) Immunofluorescence staining of MC1-R (red) and the endothelial cell marker CD31 (green) in the liver of a chow-fed C57Bl/6 J mouse. (<bold>C</bold>) Immunofluorescence staining of MC1-R (red) and the macrophage marker Mac-2 (green) in the liver of a chow-fed C57Bl/6 J mouse. White arrows indicate co-localization of MC1-R and CK-19 or Mac-2. Scale bar, 20 μm in all images.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Pre-adsorption control for Melanocortin 1 receptor (MC1-R) Western blotting.</title><p>Western blot analysis of MC1-R protein expression in the mouse liver, HepG2, and mouse heart samples. The expression of β-actin is shown as a loading control. Lanes on the right (same samples as on the left) were incubated in an anti-MC1-R antibody solution that was premixed with a molar excess of a blocking MC1-R peptide.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig1-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Hepatocyte-specific Melanocortin 1 receptor (MC1-R) deficiency does not affect body weight or composition in chow-fed female mice.</title><p>(<bold>A</bold>) Representative Western blots of MC1-R and vinculin (loading control) and (<bold>B</bold>) quantification of MC1-R protein level in the liver of chow-fed control (<italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>) and Mc1r LKO mice. <italic>*p&lt;0.05</italic> versus control mice by Student’s t-test. (<bold>C</bold>) Body weight curves of chow-fed <italic>Mc1r<sup>fl/f</sup></italic><sup>l</sup>, <italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>, and Mc1r LKO mice. (<bold>D and E</bold>) Total fat and lean mass of chow-fed <italic>Mc1r<sup>fl/f</sup></italic><sup>l</sup>, <italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>, and Mc1r LKO mice at the start and end of the body weight monitoring period. The change in fat and lean mass between the start and end of the experiment is also presented in the graphs. Values are mean ± SEM, mice n=5–10 mice per group in each graph.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig1-figsupp3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig1-figsupp3-v1.tif"/></fig></fig-group><p>To determine the regulatory role of MC1-R in the liver, we generated hepatocyte-specific MC1-R knock-out mice (<italic>Mc1r<sup>fl/fl</sup> Alb<sup>Cre/+</sup></italic>; denoted as Mc1r LKO) by crossing MC1-R floxed (<italic>Mc1r<sup>fl/fl</sup></italic>) mice with transgenic mice expressing Cre recombinase under the control of the mouse albumin promoter (<italic>Alb<sup>Cre/+</sup></italic>) (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Genotyping of the liver samples verified efficient recombination of the loxP-flanked allele in Mc1r LKO mice (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) that resulted in significant downregulation of hepatic <italic>Mc1r</italic> mRNA expression in these mice compared to control <italic>Mc1r<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). A gene dosage effect was also noted in this regard as <italic>Alb<sup>Cre/+</sup></italic> mice that were heterozygous for the <italic>Mc1r</italic> floxed allele (<italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>) showed only partial downregulation of <italic>Mc1r</italic> compared to Mc1r LKO mice (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Western blotting also showed significantly reduced MC1-R protein expression in the liver of Mc1r LKO mice (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> and <xref ref-type="supplementary-material" rid="fig1s3sdata1">Figure 1—figure supplement 3—source data 1</xref>). To evaluate the effect of hepatocyte-specific MC1-R deficiency on body weight development, <italic>Mc1r<sup>fl/fl</sup></italic>, <italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>, and Mc1r LKO mice were fed a normal chow diet and weighed weekly during a monitoring period from 8 to 16 weeks of age. However, no differences were observed in body weight between the genotypes (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Body composition analysis by quantitative NMR scanning at the start and end of the monitoring period did not reveal any significant changes in total fat or lean mass of Mc1r LKO mice compared to control genotypes (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Of note, Mc1r LKO mice displayed a significant increase in liver weight (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), which became more evident when calculated as the percentage of body weight (<xref ref-type="fig" rid="fig1">Figure 1H</xref>). Since the relative liver weight was significantly increased in comparison with both control groups, we used <italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic> mice as the control group in subsequent analyses to eliminate the possible confounding by Alb-Cre transgene expression.</p><p>Histological examination by H&amp;E and Oil Red O staining revealed an enhanced accumulation of intracellular lipid droplets in the liver of Mc1r LKO mice in comparison to the control (<italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>) mice (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Supporting this finding, quantification of hepatic lipid content showed increased TG and total cholesterol levels in Mc1r LKO mice (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). Likewise, plasma TG and TC levels were significantly higher in Mc1r LKO mice compared to control mice (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). Mc1r LKO mice also demonstrated signs of increased liver fibrosis, as evidenced by Picrosirius Red staining and gene expression analysis of fibrotic genes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref><bold>)</bold>. However, no change in the expression of pro-inflammatory genes was observed between the genotypes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref><bold>)</bold>. In a separate experiment, mice were fed a Western diet for 12 weeks to investigate whether hepatocyte-specific MC1-R deficiency exacerbates diet-induced dyslipidemia. Western diet-fed Mc1r LKO mice did not differ from control mice in terms of body weight or composition, liver weight, or plasma lipid concentrations (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref><bold>)</bold>. However, in line with the phenotype observed in chow-fed mice, Mc1r LKO mice showed enhanced cholesterol and TG accumulation in the liver after Western diet feeding (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref><bold>)</bold>.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Hepatocyte-specific Melanocortin 1 receptor (MC1-R) deficiency enhances cholesterol and triglyceride accumulation in the liver.</title><p>(<bold>A</bold>) Representative hematoxylin and eosin (H&amp;E) and Oil Red O-stained liver sections of chow-fed control (<italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>) and Mc1r LKO mice. Scale bar, 50 µm. (<bold>B, C</bold>) Quantification of liver total cholesterol and triglyceride content in chow-fed control and Mc1r LKO mice. (<bold>D, E</bold>) Quantification of plasma total cholesterol and triglyceride concentrations in chow-fed control and Mc1r LKO mice. (<bold>F</bold>) Representative Western blots of SREBP2, HMGCR, DHCR7, and vinculin (loading control) expression in the liver of chow-fed control and Mc1r LKO mice. (<bold>G</bold>) Quantification of mature and precursor forms SREBP2 as well as their ratio (precursor-to-mature) in the liver of chow-fed control and Mc1r LKO mice. (<bold>H</bold>) Quantification of HMGCR and DHCR7 protein levels in the liver of chow-fed control and Mc1r LKO mice. Values are mean ± SEM, n=6–10 mice per group in each graph. *p<italic>&lt;0.05</italic> and **p<italic>&lt;0.01</italic> versus control mice by Student’s t-test. SREBP2, sterol regulatory element binding protein 2; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; DHCR7, 7-dehydrocholesterol reductase.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig2">Figure 2F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Hepatocyte-specific melanocortin 1 receptor (MC1-R) deficiency enhances liver fibrosis.</title><p>(<bold>A</bold>) Representative Picrosirius Red-stained liver sections of chow-fed control (<italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>) and Mc1r LKO mice. Scale bar, 100 µm. (<bold>B</bold>) Quantification of fibrotic area (as a percentage of total tissue area) in the liver of chow-fed control and Mc1r LKO mice. n=5 mice per group. Quantitative real-time polymerase chain reaction (qPCR) analysis of fibrotic (<bold>C</bold>) and pro-inflammatory (<bold>D</bold>) genes in the liver of chow-fed control and Mc1r LKO mice. Values are mean ± SEM, mice n=8–10 mice per group in each graph. *p&lt;0.05 and **p&lt;0.01 for the indicated comparisons by Student’s t-test. <italic>Col1a1</italic>, collagen, type I, alpha 1; <italic>Tgfb1</italic>, transforming growth factor beta 1; <italic>Mmp2</italic>, matrix metalloproteinase-2; <italic>Il1b</italic>, interleukin 1 beta; <italic>Il6</italic>, interleukin 6; <italic>Tnf</italic>, tumor necrosis factor; <italic>Ccl2</italic>, chemokine (C-C motif) ligand 2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Hepatocyte-specific melanocortin 1 receptor (MC1-R) deficiency does not affect body or liver weight in Western diet-fed female mice, but aggravates hepatic cholesterol and triglyceride accumulation.</title><p>(<bold>A</bold>) Body weight curves of Western diet-fed control (<italic>Mc1r<sup>fl/fl</sup></italic>) and Mc1r LKO mice. (<bold>B and C</bold>) Absolute liver weight and liver to body weight ratio (expressed as a percentage of body weight) in Western diet-fed control and Mc1r LKO mice (<bold>D and E</bold>) Total fat and lean mass of HFD-fed control and Mc1r LKO mice at the start and end of the body weight monitoring period. The change in fat and lean mass between the start and end of the experiment is also presented in the graphs. (<bold>F and G</bold>) Quantification of plasma total cholesterol and triglyceride concentrations in Western diet-fed control and Mc1r LKO mice. (<bold>H and I</bold>) Quantification of liver total cholesterol and triglyceride concentrations in Western diet-fed control and Mc1r LKO mice. Values are mean ± SEM, mice n=15 (control) and 6 (Mc1r LKO) mice per group. *p&lt;0.05 and <italic>**p</italic>&lt;0.01 versus Mc1r<sup>fl/fl</sup> mice by Student’s t-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig2-figsupp2-v1.tif"/></fig></fig-group><p>We next quantified protein levels of genes involved in cholesterol synthesis by Western blotting. We found that the expression of the cleaved mature form (70 kDa) or the full-length precursor form (120 kDa) of sterol regulatory element binding protein 2 (SREBP2), which is the master transcriptional regulator of cholesterol homeostasis, was not significantly changed in the liver of chow-fed Mc1r LKO mice. However, the ratio between the mature and precursor forms of SREB2 was reduced in Mc1r LKO mice (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). Consequently, the protein levels of SREBP2 target 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and 7-dehydrocholesterol reductase (DHCR7), which are crucially involved in the biosynthesis of cholesterol (<xref ref-type="bibr" rid="bib45">Prabhu et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Shi et al., 2022</xref>), were also significantly reduced in Mc1r LKO mice (<xref ref-type="fig" rid="fig2">Figure 2F and H</xref>).</p></sec><sec id="s2-2"><title>Hepatocyte-specific MC1-R deficiency disturbs bile acid metabolism</title><p>Based on the previous finding of disturbed bile acid metabolism in global MC1-R deficient mice on <italic>Apoe<sup>-/-</sup></italic> background (<xref ref-type="bibr" rid="bib52">Rinne et al., 2018</xref>), we were curious to investigate whether the hepatocyte-specific MC1-R knockout model recapitulates this phenotype. To this end, we quantified total and individual bile acids (BA) in the liver, feces, and plasma of chow-fed Mc1r LKO mice by liquid chromatography-mass spectrometry. We found that the total amount of BAs was markedly reduced in the plasma and to some extent (p=0.06) also in the feces of Mc1r LKO mice (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>), while the size of hepatic BA pool remained unchanged (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). These changes were largely attributable to the reduction in secondary BAs (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). Quantification of primary BA species in the plasma revealed that the levels of taurine-conjugated cholic acid (CA) and ursodeoxycholic acid (UDCA) were lower in Mc1r LKO mice. In terms of secondary BAs, Mc1r LKO mice showed significantly reduced plasma levels of taurine-conjugated deoxycholic acid (DCA), hyodeoxycholic acid (HDCA), and ω-muricholic acid (ω-MCA) (<xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>). The amount of DCA was also lower in the liver of Mc1r LKO mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig3s1sdata1">Figure 3—figure supplement 1—source data 1</xref>), while in the feces, HDCA, litocholic acid (LCA) and 12-keto litocholic acid (12-oxo LCA), which is the primary metabolite of DCA, were significantly reduced by MC1-R deficiency (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig3s1sdata2">Figure 3—figure supplement 1—source data 2</xref>). Furthermore, the relative proportions of primary BAs in the plasma indicate that hepatocyte-specific MC1-R deficiency reduced the amount of CA with an accompanying increase in CDCA and UDCA (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). This BA profile is further reflected as a significant reduction in the plasma ratio of CA:CDCA (<xref ref-type="fig" rid="fig3">Figure 3G</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Hepatocyte-specific melanocortin 1 receptor (MC1-R) deficiency disturbs bile acid metabolism.</title><p>(<bold>A–C</bold>) Quantification of total, primary, and secondary bile acids in the liver, plasma and feces of chow-fed control (<italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>), and Mc1r LKO mice. (<bold>D</bold>) Quantification of individual primary bile acids in the plasma of chow-fed control and Mc1r LKO mice. (<bold>E</bold>) Quantification of individual secondary bile acids in the plasma of chow-fed control and Mc1r LKO mice. (<bold>F</bold>) Relative proportions of individual primary bile acids in the plasma of chow-fed control and Mc1r LKO mice. (<bold>G</bold>) The ratio of cholic acid (CA) to chenodeoxycholic acid (CDCA) in the plasma of chow-fed control and Mc1r LKO mice. Values are mean ± SEM, n=4–5 mice per group in each graph. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001<italic>,</italic> and ****p&lt;0.0001 versus control mice by Student’s t-test. CA indicates cholic acid; CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid; MCA, muricholic acid; DCA, deoxycholic acid; LCA, litocholic acid; HDCA, hyodeoxycholic acid (HDCA).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) analysis of individual bile acids in the plasma.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84782-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Bile acid profiles in the liver and feces of Mc1r LKO mice.</title><p>(<bold>A</bold>) Quantification of individual primary bile acids in the liver of chow-fed control (<italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>) and Mc1r LKO mice. (<bold>B</bold>) Quantification of individual secondary bile acids in the liver of chow-fed control and Mc1r LKO mice. (<bold>C</bold>) Quantification of individual primary bile acids in the feces of chow-fed control and Mc1r LKO mice. (<bold>D</bold>) Quantification of individual secondary bile acids in the feces of chow-fed control and Mc1r LKO mice. Values are mean ± SEM, mice n=4–5 mice per group in each graph. *p&lt;0.05 for the indicated comparisons by Student’s t-test. CA indicates cholic acid; CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid; MCA, muricholic acid; DCA, deoxycholic acid; LCA, litocholic acid; HDCA, hyodeoxycholic acid.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) analysis of individual bile acids in the liver.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84782-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) analysis of individual bile acids in the feces.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84782-fig3-figsupp1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig3-figsupp1-v1.tif"/></fig></fig-group><p>To address possible causes of disturbed BA metabolism in Mc1r LKO mice, we quantified the hepatic expression of genes encoding for BA synthetizing enzymes (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Although the expression of cholesterol 7 alpha-hydroxylase (encoded by <italic>Cyp7a1</italic>), which is the first and rate-liming enzyme in BA synthesis (<xref ref-type="bibr" rid="bib8">Chiang, 2004</xref>), was unchanged, Mc1r LKO mice demonstrated significant upregulation of sterol 12α-hydroxylase (encoded by <italic>Cyp8b1</italic>) and sterol 27-hydroxylase (encoded by <italic>Cyp27a1</italic>) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Furthermore, Mc1r LKO mice had reduced mRNA levels of steroidogenic acute regulatory protein 1 (<italic>Stard1</italic>), which facilitates the trafficking of cholesterol to mitochondria and thus feeds the alternative mitochondrial pathway of BA synthesis (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; <xref ref-type="bibr" rid="bib42">Pandak et al., 2002</xref>; <xref ref-type="bibr" rid="bib49">Ren et al., 2004</xref>). Second, we quantified the hepatic mRNA levels of transporters responsible for the uptake of BAs and their excretion into bile and systemic circulation (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We found that the expression of sodium/bile acid cotransporter (encoded by <italic>Ntcp</italic>), which accounts for the majority (~90%) of BA uptake from the portal circulation (<xref ref-type="bibr" rid="bib12">Dawson et al., 2009</xref>), was upregulated in the liver of Mc1r LKO mice, while bile salt export pump (<italic>Bsep</italic>) showed no change at the mRNA level (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). An alternative basolateral export of BAs is mediated by the heterodimeric organic solute transporter OSTα/OSTβ and the multidrug resistance-associated proteins MRP3 and MRP4 (<xref ref-type="bibr" rid="bib12">Dawson et al., 2009</xref>), the last of which was downregulated in Mc1r LKO mice (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Third, among different nuclear receptors that regulate the transcription of BA enzymes and transporters, farnesoid X receptor (<italic>Fxr</italic>) and hepatocyte nuclear factor 4α (<italic>Hnf4a</italic>) were significantly upregulated in the liver of Mc1r LKO mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Hepatocyte-specific melanocortin 1 receptor (MC1-R) deficiency affects the expression of genes involved in bile acid synthesis and transport.</title><p>(<bold>A, B</bold>) Quantitative real-time polymerase chain reaction (qPCR) analysis of genes involved in the bile acid synthesis and transport in the liver of chow-fed control (<italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic>) and Mc1r LKO mice. (<bold>C</bold>) qPCR analysis of nuclear receptor genes that regulate the transcription of bile acid enzymes and transporters. (<bold>D, E</bold>) Representative Western blots and quantification of CYP8B1, StAR, and MRP4 protein levels in the liver of chow-fed control and Mc1r LKO mice. Values are mean ± SEM, n=7–10 mice per group in each graph. *p&lt;0.05, **p<italic>&lt;</italic>0.01, and ***p&lt;0.001 versus control mice by Student’s t-test. <italic>Cyp7a1</italic>, cholesterol 7 alpha-hydroxylase; <italic>Cyp7b1</italic>, 25-hydroxycholesterol 7-alpha-hydroxylase; <italic>Cyp8b1</italic>, sterol 12-alpha-hydroxylase; <italic>Cyp27a1</italic>, sterol 27- hydroxylase; <italic>Stard1</italic>, steroidogenic acute regulatory protein; <italic>Fxr</italic>, farnesoid X receptor; <italic>Lrh1</italic>, liver receptor homologue 1; <italic>Bsep</italic>, bile-salt export pump; <italic>Ntcp</italic>, Na<sup>+</sup>-taurocholate cotransporting polypeptide; <italic>Hnf4a</italic>, hepatocyte nuclear factor 4 alpha.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig4-v1.tif"/></fig><p>Finally, we selected the genes, which were differently expressed in Mc1r LKO mice and could potentially explain the observed BA profile in these mice, and quantified the corresponding protein levels of these gene products in the liver by Western blotting. In good agreement with the mRNA level changes, Mc1r LKO mice showed higher CYP8B1 and lower MRP4 protein expression compared to control mice (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref> and <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). However, StAR (encoded by <italic>Stard1</italic>) protein level was significantly increased in the liver of Mc1r LKO mice (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>), which contradicts the mRNA level finding.</p></sec><sec id="s2-3"><title>The endogenous MC1-R agonist α-MSH reduces cellular cholesterol content and enhances LDL and HDL uptake in HepG2 cells</title><p>The finding of MC1-R expression in the mouse liver and the phenotype of enhanced cholesterol accumulation in Mc1r LKO mice led us to investigate the effects and underlying mechanisms of MC1-R activation in human HepG2 cells. First, we aimed to verify that human hepatocytes also express MC1-R. Indeed, HepG2 cells clearly express MC1-R protein (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). Consistent with the finding of reduced MC1-R expression in the liver of Western diet-fed mice, loading of HepG2 cells with palmitic acid (a saturated free fatty acid) caused a rapid decrease of MC1-R protein expression (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). However, exposure of HepG2 cells to excess LDL cholesterol (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>) or treatment with the HMGCR inhibitor atorvastatin (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>) to lower cellular cholesterol content did not change MC1-R protein level. Second, we studied how MC1-R activation affects cholesterol metabolism in HepG2 cells. For this purpose, HepG2 cells were stimulated with the endogenous MC1-R agonist α-MSH and the amount of cellular free cholesterol was quantified using Filipin staining. We observed that α-MSH (1 µM) significantly decreased the free cholesterol content in HepG2 cells with an effect appearing after 3 hr and plateauing towards the 24 hr time point (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). In terms of concentration-responsiveness, cholesterol content was already reduced with a subnanomolar concentration (0.1 nM) of α-MSH, and the maximal response was achieved with 1 µM α-MSH (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). The reduction in cellular cholesterol was accompanied by significant increases in LDL and HDL uptake (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>), as evaluated after 24 hr treatment with α-MSH using fluorescently labeled lipoprotein particles (Dil-LDL and Dil-HDL). In good agreement with these findings, gene expression analysis revealed that α-MSH upregulated LDL receptor (<italic>LDLR</italic>) and the HDL receptor SR-BI (<italic>SCARB1</italic>) mRNA levels in a concentration-dependent manner (<xref ref-type="fig" rid="fig5">Figure 5H,I</xref>). These effects were only apparent at a 3 hr time point, which probably reflects the short half-life of α-MSH (<xref ref-type="bibr" rid="bib47">Redding et al., 1978</xref>; <xref ref-type="bibr" rid="bib55">Rudman et al., 1983</xref>). Nevertheless, upregulated <italic>LDLR</italic> and <italic>SCARB1</italic> mRNA levels translated into more sustained increases in the corresponding protein levels (LDLR and SR-BI) after α-MSH treatment (<xref ref-type="fig" rid="fig5">Figure 5I and J</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). Protein level analyses further showed that α-MSH had no effect on the expression of the cholesterol biosynthetic enzymes HMGCR and DHCR7 (<xref ref-type="fig" rid="fig5">Figure 5J and K</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). Intriguingly, we observed that LDLR expression at the cell surface, as quantified by flow cytometry, was markedly increased already after 1 hr of treatment with 1 µM α-MSH (<xref ref-type="fig" rid="fig5">Figure 5L</xref>). Finally, in terms of BA metabolism, it appeared that α-MSH increased CA concentration in the culture medium of HepG2 cells without any effect on CDCA concentration (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref>). Consequently, the ratio of CA to CDCA was significantly increased in response to α-MSH treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Supporting this finding, Western blotting analysis showed that α-MSH upregulated CYP8B1 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and ), which is the major determinant of CA:CDCA ratio (<xref ref-type="bibr" rid="bib43">Pandak and Kakiyama, 2019</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The endogenous melanocortin 1 receptor (MC1-R) agonist α-MSH reduces cellular cholesterol content and enhances low-density lipoprotein (LDL) and high-density lipoprotein (HDL) uptake in HepG2 cells.</title><p>(<bold>A–C</bold>) Representative Western blots and quantification of MC1-R protein level in HepG2 cells treated with palmitic acid (500 µM), LDL (200 µg/ml), or atorvastatin (10 µM) for 1, 3, 6, or 24 hr. (<bold>D</bold>) Quantification of free cholesterol content using filipin staining in HepG2 cells treated with α-MSH (1 µM) for 1, 3, 6, or 24 hr. (<bold>E</bold>) Quantification of free cholesterol content in HepG2 cells treated with different concentrations of α-MSH (0.1 nM, 10 nM, or 1 µM) for 24 hr. (<bold>F, G</bold>) Quantification of LDL and HDL uptake in HepG2 cells treated with different concentrations (0.1 nM, 10 nM, or 1 µM) of α-MSH for 24 hr. (<bold>H, I</bold>) Quantitative real-time polymerase chain reaction (qPCR) analysis of LDL receptor (<italic>LDLR)</italic> and <italic>SCARB1</italic> expression in HepG2 cells treated with different concentrations of α-MSH for 3, 6, or 24 hr. (<bold>J, K</bold>) Representative Western blots and quantification of LDL-R and SR-BI proteins levels in HepG2 cells treated with 1 µM α-MSH for 1, 3, 6, or 24 hr. (<bold>L</bold>) Quantification of cell surface LDLR by flow cytometry in HepG2 cells treated with 1 µM α-MSH for 24 hr. Values are mean ± SEM, n=3–6 per group in each graph. *p&lt;0.05 and **p<italic>&lt;0.01</italic> for the indicated comparisons by one-way ANOVA and Dunnet <italic>post hoc</italic> tests (<bold>A–K</bold>) or by Student’s t-test (<bold>L</bold>).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig5">Figure 5A, B, C and J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig5-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The effects of α-MSH on bile acid production in HepG2 cells.</title><p>(<bold>A</bold>) Quantification of cholic acid (CA) and chenodeoxycholic acid (CDCA) in the culture medium of HepG2 cells treated with 1 µM α-MSH for 24 hr. (<bold>B</bold>) The ratio of CA to CDCA in the culture medium of HepG2 cells treated with 1 µM α-MSH for 24 hr. n=3–4 per group in each graph. (<bold>C</bold>) Representative Western blots and quantification of CYP8B1 in HepG2 cells treated with 1 µM α-MSH for 1, 3, 6, or 24 hr. n=4–6 per group. Values are mean ± SEM, *p&lt;0.05 for the indicated comparisons by Student’s t-test (<bold>A and B</bold>) or by one-way ANOVA and Dunnet <italic>post hoc</italic> tests (<bold>C</bold>).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) analysis of individual bile acids in the cell culture medium.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84782-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Selective activation of MC1-R mimics the effects of α-MSH in HepG2 cells</title><p>Since α-MSH can also bind and activate other MC-R subtypes, we aimed to verify that the effects induced by α-MSH were particularly derived from the activation of MC1-R. To this end, we repeated the key experiments using LD211, which is a highly potent and selective agonist for MC1-R with no detectable binding to other MC-R subtypes (<xref ref-type="bibr" rid="bib14">Doedens et al., 2010</xref>). Closely mirroring the effect observed with α-MSH, selective activation of MC1-R with LD211 led to a concentration-dependent reduction in cellular cholesterol amount (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). LD211 also significantly increased LDL and HDL uptake (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>), which was accompanied by upregulation of <italic>LDLR</italic> and <italic>SCARB1</italic> mRNA expression (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). In comparison with α-MSH (<xref ref-type="fig" rid="fig4">Figure 4G and H</xref>), LD211 caused more sustained changes in gene expression (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), which could be explained by the cyclic and more stable structure of LD211 (<xref ref-type="bibr" rid="bib14">Doedens et al., 2010</xref>). Despite the clear-cut effects observed at the mRNA level, LD211 did not significantly affect LDLR and SR-BI protein levels, as detected by Western blotting (<xref ref-type="fig" rid="fig6">Figure 6E</xref> and <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref><bold>)</bold>. However, the cell surface expression of LDLR, which is a major determinant of LDL uptake rate, was markedly increased in HepG2 cells after 3-, 6-, and 24 hr treatment with LD211 (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Finally, the subnanomolar concentration of LD211 also down-regulated the fibrosis-associated genes <italic>TGFB1</italic>, <italic>ACTA2,</italic> and <italic>COL1A1</italic> in HepG2 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). α-MSH appeared to also downregulate the expression of the fibrotic genes <italic>TGFB1</italic> and <italic>COL1A1</italic> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), but these changes did not reach statistical significance (p=0.08 and 0.051, respectively). Taken together, these results demonstrate that the α-MSH-induced effects were largely reproducible by selective MC1-R activation with LD211.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Selective activation of melanocortin 1 receptor (MC1-R) mimics the actions of α-MSH in HepG2 cells.</title><p>(<bold>A</bold>) Quantification of free cholesterol content using filipin staining in HepG2 cells treated with different concentrations of the selective MC1-R agonist LD211 (0.1 nM, 10 nM, or 1 µM) for 24 hr. (<bold>B, C</bold>) Quantification of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) uptake in HepG2 cells treated with different concentrations (0.1 nM, 10 nM, or 1 µM) of LD211 for 24 hr. (<bold>D</bold>) Quantitative real-time polymerase chain reaction (qPCR) analysis of LDL receptor (<italic>LDLR)</italic> and <italic>SCARB1</italic> expression in HepG2 cells treated with 1 µM LD211 for 3, 6, or 24 hr. (<bold>E</bold>) Representative Western blots and quantification of LDL-R and SR-BI proteins levels in HepG2 cells treated with 1 µM LD211 for 1, 3, 6, or 24 hr. (<bold>F</bold>) Quantification of cell surface LDLR by flow cytometry in HepG2 cells treated with 1 µM LD211 for 24 hr. Values are mean ± SEM, n=3–6 per group in each graph. *p&lt;0.05<italic>,</italic> **p&lt;0.01<italic>,</italic> ***p&lt;0.001<italic>,</italic> and ****p&lt;0.0001 for the indicated comparisons by one-way ANOVA and Dunnet <italic>post hoc</italic> tests.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig6">Figure 6E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>The effects of α-MSH and the selective melanocortin 1 receptor (MC1-R) agonist LD211 on the expression of pro-inflammatory and fibrotic genes in HepG2 cells.</title><p>(<bold>A</bold>) Quantitative real-time polymerase chain reaction (qPCR) analysis of <italic>TGFB1</italic>, <italic>ACTA1</italic>, <italic>ACTA2</italic>, <italic>COL1A1</italic>, <italic>TNF,</italic> and <italic>IL6</italic> expression in HepG2 cells treated with different concentrations of α-MSH for 3 or 6 hr. (<bold>B</bold>) qPCR analysis of <italic>TGFB1</italic>, <italic>ACTA1</italic>, <italic>ACTA2</italic>, <italic>COL1A1</italic>, <italic>TNF,</italic> and <italic>IL6</italic> expression in HepG2 cells treated with different concentrations of LD211 for 3 or 6 hr. n=4–5 per group in each graph. Values are mean ± SEM, *p&lt;0.05 and **p&lt;0.01 for the indicated comparisons by one-way ANOVA and Dunnet <italic>post hoc</italic> tests.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>MC1-R activation engages multiple signaling mechanisms to regulate cholesterol metabolism in HepG2 cells</title><p>We next aimed to investigate intracellular signaling cascades that might be activated in response to MC1-R stimulation. Since most MC-Rs are known to be coupled to Gs proteins, we first measured intracellular cAMP levels in α-MSH-treated HepG2 cells. However, α-MSH did not either increase or decrease cAMP levels, while the adenylyl cyclase activator forskolin, as a positive control, induced a robust increase in cAMP level (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). We also screened other potential signaling pathways of MC1-R and found that mitogen-activated protein kinases, ERK (extracellular-signal-regulated kinase) and JNK (c-Jun N-terminal kinase), are affected by α-MSH treatment. The highest concentration of α-MSH (1 µM) reduced ERK phosphorylation (p-ERK1/2) at 5- and 15 min time points (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Profiling of the concentration-response however revealed that the phosphorylation levels of ERK and JNK are most significantly reduced at the lowest tested concentration (0.1 nM) of α-MSH and the effects tend to fade away towards higher concentrations (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>). In addition, α-MSH induced a rapid phosphorylation (at 5 min) of AMP-activated protein kinase (AMPK) (<xref ref-type="fig" rid="fig7">Figure 7D</xref> and <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>), and the maximal effect was observed with 1 µM concentration (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig7s1sdata1">Figure 7—figure supplement 1—source data 1</xref>), indicating a more conventional concentration-response. Finally, we tested whether the α-MSH-induced reduction in cellular cholesterol content is mediated by AMPK phosphorylation. Interestingly, the AMPK inhibitor dorsomorphin increased cholesterol content and reversed the concentration-response to α-MSH (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). In the presence of dorsomorphin, the lowest concentration of α-MSH showed the strongest response, while the effect of 1 µM α-MSH was completely blocked (<xref ref-type="fig" rid="fig7">Figure 7E</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>The effects of α-MSH on intracellular signaling pathways in HepG2 cells.</title><p>(<bold>A</bold>) Quantification of intracellular cAMP level in HepG2 cells treated with different concentrations of α-MSH (0.1 nM, 10 nM, or 1 µM) for 30 min. The adenylyl cyclase activator forskolin (10 µM) was used as a positive control. (<bold>B, C</bold>) Quantification of phosphorylated ERK1/2 and JNK by ELISA assays in HepG2 cells treated with different concentrations of α-MSH (0.1 nM, 10 nM, or 1 µM) for 10 min. (<bold>D</bold>) Representative Western blots and quantification of phosphorylated AMPK level (p-AMPK normalized against total AMPK) in HepG2 cells treated with 1 µM α-MSH for 5, 15, 30, or 60 min. (<bold>E</bold>) Quantification of free cholesterol content using filipin staining in HepG2 cells treated with different concentrations of α-MSH (0.1 nM, 10 nM, or 1 µM) for 24 hr in the presence or absence of the AMP-activated protein kinase (AMPK) inhibitor dorsomorphin (1 µM). Values are mean ± SEM, n=3–6 per group in each graph. *p&lt;0.05<italic>,</italic> **p&lt;0.01<italic>,</italic> and ****p&lt;0.0001 for the indicated comparisons by one-way ANOVA and Dunnet <italic>post hoc</italic> tests.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig7-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>The effects of α-MSH on the phosphorylation of ERK1/2 and AMP-activated protein kinase (AMPK) in HepG2 cells.</title><p>(<bold>A</bold>) Quantification of phosphorylated ERK1/2 by ELISA assay in HepG2 cells treated with 1 µM α-MSH for 5, 15, 30, or 60 min. **p&lt;0.01 and ***p&lt;0.001 versus Control (0 min). (<bold>C</bold>) Representative Western blots and quantification of phosphorylated AMPK level (normalized against total AMPK) in HepG2 cells treated with different concentrations of α-MSH (0.1 nM, 10 nM, or 1 µM) for 5 min. Values are mean ± SEM, *p&lt;0.05 for the indicated comparisons by one-way ANOVA and Dunnet <italic>post hoc</italic> tests. n=4–6 per group in each graph.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig7-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>The effects of the selective melanocortin 1 receptor (MC1-R) agonist LD211 on intracellular signaling pathways in HepG2 cells.</title><p>(<bold>A</bold>) Quantification of intracellular cAMP level in HepG2 cells treated with different concentrations of LD211 (0.1 nM, 10 nM, or 1 µM) for 30 min. The adenylyl cyclase activator forskolin (10 µM) was used as a positive control. (<bold>B and C</bold>) Quantification of phosphorylated ERK1/2 and c-Jun N-terminal kinase (JNK) by ELISA assays in HepG2 cells treated with different concentrations of LD211 (0.1 nM, 10 nM, or 1 µM) for 10 min. (<bold>D</bold>) Representative Western blots and quantification of phosphorylated AMPK level (p-AMPK normalized against total AMP-activated protein kinase (AMPK)) in HepG2 cells treated with 1 µM LD211 for 5, 15, 30, or 60 min. (<bold>E</bold>) Quantification of free cholesterol content using filipin staining in HepG2 cells treated with different concentrations of LD211 (0.1 nM, 10 nM, or 1 µM) for 24 hr in the presence or absence of the AMPK inhibitor dorsomorphin (1 µM). Values are mean ± SEM, *p&lt;0.05, **p&lt;0.01<italic>,</italic> ***p&lt;0.001<italic>,</italic> and ****p&lt;0.0001 for the indicated comparisons by one-way ANOVA and Dunnet <italic>post hoc</italic> tests. n=4–6 per group in each graph.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>Uncropped Western blots for <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84782-fig7-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig7-figsupp2-v1.tif"/></fig></fig-group><p>To verify the dependence of the observed effects on MC1-R activation, we repeated the signaling experiments using LD211 as a selective MC1-R agonist. LD211 had no effect on cAMP level (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>) but reduced the phosphorylation level of ERK1/2 and JNK (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref><bold>)</bold> and induced phosphorylation of AMPK (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref> and <xref ref-type="supplementary-material" rid="fig7s2sdata1">Figure 7—figure supplement 2—source data 1</xref><bold>)</bold>, thus closely matching the phenotype of α-MSH-treated cells. Furthermore, we observed that AMPK inhibition with dorsomorphin completely abolished the cholesterol-lowering effect of LD211 (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref><bold>)</bold>. Collectively, the results demonstrate that α-MSH evokes multiple signaling pathways and that the effects of α-MSH on cholesterol metabolism are not reliant on one single pathway.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the present study, we investigated the role of MC1-R in hepatocytes and its possible involvement in cholesterol and bile acid metabolism. First, extending previous observations on the hepatic expression of <italic>Mc1r</italic> mRNA, we show that MC1-R protein is widely present in the mouse liver and downregulated in response to feeding a cholesterol-rich diet. Second, hepatocyte-specific MC1-R deficiency rendered mice susceptible to enhanced accumulation of cholesterol and triglycerides in the plasma and liver (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Loss of MC1-R signaling in hepatocytes disturbed also bile acid metabolism. Third, in vitro experiments using HepG2 cells revealed that triggering MC1-R signaling either with the endogenous ligand α-MSH or the selective MC1-R agonist LD211 reduced cellular cholesterol content and enhanced the uptake of HDL and LDL cholesterol (<xref ref-type="fig" rid="fig8">Figure 8</xref>), which are preventive mechanisms against hypercholesteremia and associated cardiovascular complications.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Schematic figure illustrates the role of melanocortin 1 receptor (MC1-R) in regulating cholesterol and bile acid homeostasis.</title><p>Hepatocyte-specific MC1-R deficiency enhanced the accumulation of cholesterol and triglycerides (TG) in the liver, promoted fibrogenesis, and lead to a disturbance in bile acid metabolism. Conversely, activation of MC1-R with the endogenous agonist α-MSH or the synthetic agonist LD211 reduced cellular cholesterol levels and increased the uptake of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles in cultured HepG2 cells. p-AMPK indicates phosphorylated AMP-activated protein kinase; p-ERK1/2, phosphorylated extracellular-signal-regulated kinase 1/2; p-JNK, phosphorylated c-Jun N-terminal kinase. The figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-fig8-v1.tif"/></fig><p>Previous findings of <italic>MC1R</italic> mRNA expression in the rat and human liver (<xref ref-type="bibr" rid="bib18">Gatti et al., 2006</xref>; <xref ref-type="bibr" rid="bib33">López et al., 2007</xref>; <xref ref-type="bibr" rid="bib34">Malik et al., 2012</xref>) and that global MC1-R deficiency aggravated hypercholesterolemia in Apoe<sup>-/-</sup> mice (<xref ref-type="bibr" rid="bib52">Rinne et al., 2018</xref>) led us to hypothesize that MC1-R regulates cholesterol metabolism in hepatocytes. <italic>Mc1r</italic> mRNA expression in the rat liver was previously found to increase after turpentine oil-induced acute phase response (<xref ref-type="bibr" rid="bib34">Malik et al., 2012</xref>), while <italic>MC1R</italic> was downregulated in liver biopsies from brain-dead organ donors (<xref ref-type="bibr" rid="bib18">Gatti et al., 2006</xref>), suggesting that inflammatory processes might modulate hepatic MC1-R expression. Here, we show that the MC1-R is present also in the mouse liver where it localizes mainly in hepatocytes but also in other cell types such as cholangiocytes. Of note, hepatic MC1-R mRNA and protein levels were reduced after feeding mice a cholesterol-rich Western diet. Consistently, hepatic <italic>MC1R</italic> expression was downregulated in patients with NAFLD or NASH. We also analyzed MC1-R expression in HepG2 cells to gain further insight into the regulation of MC1-R expression in hepatocytes. Intriguingly, acute changes in cellular cholesterol load, as produced by treatment with atorvastatin or LDL-cholesterol, did not affect the MC1-R protein level, while treatment with palmitic acid evoked an immediate reduction in MC1-R expression. These findings suggest that cholesterol per se does not regulate MC1-R expression but it might be rather modulated by inflammatory processes that are triggered by lipid overload.</p><p>To investigate the regulatory role of hepatic MC1-R, we generated Mc1r LKO mice and found that hepatocyte-specific MC1-R deficiency induced hypercholesteremia and higher liver weight, which was accompanied by increased total cholesterol and triglyceride levels in the liver. Mc1r LKO mice closely phenocopied the features of <italic>Apoe<sup>-/-</sup></italic> mice with global deficiency of MC1-R (<xref ref-type="bibr" rid="bib52">Rinne et al., 2018</xref>), which displayed enhanced hypercholesteremia and cholesterol accumulation in the liver. Thus, the present findings suggest that the disturbed cholesterol metabolism previously observed in global MC1-R deficient mice was attributable to the loss of MC1-R signaling in hepatocytes. The precise mechanism leading to enhanced hepatic lipid accumulation and hypercholesterolemia in Mc1r LKO mice is not yet clear. Under normal physiological conditions, SREBP1c preferentially activates the genes of fatty acid and triglyceride biosynthesis pathway, while SREBP2 is considered as the master regulator of cholesterol metabolism (<xref ref-type="bibr" rid="bib22">Hua et al., 1993</xref>; <xref ref-type="bibr" rid="bib66">Yokoyama et al., 1993</xref>). In the presence of excess cellular cholesterol, transcriptional induction and posttranslational activation of SREBP2 are suppressed, which, in turn, downregulates <italic>Hmgcr</italic> and <italic>Dhcr7</italic> and reduces cholesterol synthesis as a counterregulatory mechanism. Therefore, given the increase in hepatic cholesterol content, it was expected that HMGCR and DHCR7 protein levels were reduced in the liver of Mc1r LKO mice. These data, in combination with the finding that MC1-R activation did not affect HMGCR or DHCR7 expression in HepG2 cells, could indicate that hepatic MC1-R signaling does not directly control cholesterol synthesis. Although the phenotype observed in Mc1r LKO mice might be, at least partly, caused by disturbed cholesterol conversion into bile acids, further research is warranted to dissect the exact mechanism by which hepatic MC-1R deficiency triggers hypercholesterolemia and enhanced lipid accumulation in the liver.</p><p>A central feature of the Mc1r LKO mouse model was liver steatosis that occurred on a normal chow diet and without any signs of increased susceptibility for obesity. Although the precise mechanisms leading to NAFLD remain unclear, human and animal studies have shown that under normal caloric intake, the development of NAFLD is strongly associated with disturbance in liver cholesterol metabolism (<xref ref-type="bibr" rid="bib24">Kainuma et al., 2006</xref>; <xref ref-type="bibr" rid="bib37">Min et al., 2012</xref>; <xref ref-type="bibr" rid="bib57">Simonen et al., 2011</xref>). Hence, the increased levels of plasma and liver cholesterol in Mc1r LKO mice may have secondarily led to the accumulation of triglycerides. Simple steatosis can progress to NASH that is characterized by progressive inflammation, oxidative stress, and fibrosis. Mc1r LKO mice showed enhanced liver fibrosis without any signs of elevated inflammation. Persistent lipid overload and consequent lipotoxicity could be the cause of fibrosis in Mc1r LKO mice. However, MC1-R signaling has been shown to mediate anti-fibrotic effects and protect against skin fibrosis and systemic sclerosis (<xref ref-type="bibr" rid="bib2">Böhm and Stegemann, 2014</xref>; <xref ref-type="bibr" rid="bib27">Kondo et al., 2022</xref>), which opens the possibility that hepatocyte-specific MC1-R deficiency directly induces fibrogenesis. This view is further supported by the finding that selective MC1-R activation down-regulated fibrotic genes in HepG2 cells.</p><p>Mc1r LKO mice also displayed a unique bile acid profile with reduced secondary bile acid levels, particularly in the plasma and feces. Furthermore, the ratio of CA to CDCA was reduced in the plasma of Mc1r LKO mice. This phenotype recapitulates some of the key features observed in mice with global deficiency of MC1-R (<xref ref-type="bibr" rid="bib52">Rinne et al., 2018</xref>). Specifically, the relative amount of CA and the ratio of CA to CDCA were reduced in both mouse models. In the quest for a possible explanation for this phenotype, we found that CYP8B1 was upregulated both at the mRNA and protein level in the liver of Mc1r LKO mice. This contradicts the finding of a reduced CA:CDCA ratio, which is predominantly determined by the enzymatic activity of CYP8B1 that is required for CA synthesis (<xref ref-type="bibr" rid="bib8">Chiang, 2004</xref>). Therefore, it is plausible that BA synthesis <italic>via</italic> the classical pathway is disturbed in Mc1r LKO mice due to dysfunctional CYP8B1, which leads to a compensatory enhancement of BA synthesis <italic>via</italic> the alternative pathway. This could explain the upregulation of StAR and CYP27A1, which operate in the mitochondria to feed the alternative BA pathway. Under physiological conditions, the majority of BAs are produced by the classical pathway, while in liver diseases such as NAFLD, the alternative BA pathway may become more dominant when compensating disturbances in the classical BA synthesis pathway (<xref ref-type="bibr" rid="bib8">Chiang, 2004</xref>; <xref ref-type="bibr" rid="bib11">Crosignani et al., 2007</xref>; <xref ref-type="bibr" rid="bib29">Lake et al., 2013</xref>). Patients with NASH and NASH-driven hepatocellular carcinoma have also been reported to have increased hepatic StAR expression (<xref ref-type="bibr" rid="bib5">Caballero et al., 2009</xref>; <xref ref-type="bibr" rid="bib10">Conde de la Rosa et al., 2021</xref>).</p><p>In terms of BA transport, the upregulation of NTCP and downregulation of MRP4 in Mc1r LKO mice might also indicate compensatory changes to disrupted BA synthesis. Increased NTCP is likely to enhance BA uptake from the portal circulation and thus enterohepatic circulation of BAs, while reduced MRP4 expression prevents excessive spillover of BAs into the systemic circulation. These changes synergistically help to maintain the liver BA pool in the presence of disturbed BA synthesis. Reduced MRP4 expression in Mc1r LKO mice also provides a mechanistic explanation for the finding of reduced BA levels in the plasma. It remains, however, to be determined whether the dysregulated BA metabolism contributes to the hypercholesteremia and increased hepatic lipid accumulation in Mc1r LKO mice. For instance, CYP7A1 deficiency in both humans and mice causes hypercholesterolemic phenotype with increased hepatic cholesterol content (<xref ref-type="bibr" rid="bib15">Erickson et al., 2003</xref>; <xref ref-type="bibr" rid="bib46">Pullinger et al., 2002</xref>). Because there is a reciprocal interaction between fatty liver disease and dysregulated BA metabolism, it is difficult to determine whether MC1-R deficiency per se disturbs BA metabolism or whether enhanced lipid accumulation in Mc1r LKO mice causes a defect in BA metabolism. However, in vitro experiments with HepG2 cells support the notion that hepatic MC1-R signaling might directly affect BA metabolism, since treatment with the endogenous MC1-R agonist α-MSH modestly increased CYP8B1 expression, CA synthesis, and CA:CDCA ratio. Furthermore, considering that MC1-R was expressed also in cholangiocytes and that Cre recombinase is known to be active in cholangiocytes of <italic>Alb<sup>Cre</sup></italic> transgenic mice (<xref ref-type="bibr" rid="bib30">Lemaigre, 2015</xref>), it is plausible that deficiency of MC1-R signaling in cholangiocytes contributes to the defect of BA metabolism in Mc1r LKO mice. Cholangiocytes in co-operation with hepatocytes are responsible for bile formation and secretion but these cells also significantly contribute to bile modification by absorbing bile acids and other molecules from the biliary tree and returning them to the liver sinusoids (<xref ref-type="bibr" rid="bib60">Tabibian et al., 2013</xref>).</p><p>In good agreement with our findings in Mc1r LKO mice, in vitro experiments using HepG2 cells demonstrated that triggering MC1-R signaling with the endogenous agonist α-MSH or the synthetic agonist LD211 induced a reverse phenotype, namely reduction in cellular cholesterol content. MC1-R activation was also associated with enhanced LDL and HDL uptake in HepG2 cells. Inhibition of cholesterol synthesis (e.g. by statins) is known to similarly reduce cellular cholesterol levels in hepatocytes, which, in turn, upregulates LDL-R and reduces plasma total and LDL cholesterol. In the case of MC1-R activation, the increase in LDL-R expression and LDL uptake might be partly independent of the effect on cellular cholesterol content, since the upregulation of LDL-R occurred rapidly after α-MSH treatment (at 1 hr time point) and before any noticeable change in cellular cholesterol level. Therefore, the data suggest that the upregulation of LDL-R, as well as SR-BI, is attributable mainly to direct transcriptional induction by MC1-R signaling. Supporting the therapeutic relevance of this finding, we had previously observed that chronic treatment of atherosclerotic mice with a selective MC1-R agonist increased LDL-R expression in the liver and reduced plasma total cholesterol concentration (<xref ref-type="bibr" rid="bib51">Rinne et al., 2017</xref>). The underlying mechanism remained obscure in that study, but the present findings suggest that the upregulation of LDL-R expression was a consequence of MC1-R activation in hepatocytes. In the current study, we also found that MC1-R activation reduced cellular cholesterol content in HepG2 cells but we were unable to pinpoint the exact molecular-level mechanism for this effect. Since we did not observe any change in the expression of the major cholesterol biosynthetic enzymes (HMGCR or DHCR7), we speculate that MC1-R signaling might inhibit other enzymes in the cholesterol biosynthesis pathway or modulate the phosphorylation state of HMGCR that determines its catalytic activity (<xref ref-type="bibr" rid="bib3">Burg and Espenshade, 2011</xref>). Alternatively, or in addition to other mechanisms, enhanced cholesterol turnover into BAs, as evidenced by increased CA production and CYP8B1 expression in α-MSH-treated HepG2 cells, might reduce cellular cholesterol content. In any case, these data uncover a functional role for MC1-R signaling in hepatic cholesterol metabolism that might be of therapeutic relevance in the management of hypercholesterolemia.</p><p>In terms of intracellular signaling, MC1-R activation in HepG2 cells evoked phosphorylation of AMPK and inhibition of ERK1/2 and JNK without any effect on cAMP levels. Melanocortin receptors are classically coupled to Gs protein and cAMP-dependent signaling (<xref ref-type="bibr" rid="bib54">Rodrigues et al., 2015</xref>), but the present findings demonstrate that the MC1-R-mediated effects on cholesterol metabolism occur in a cAMP-independent manner. Mechanistic experiments further revealed that the reduction of cellular cholesterol level by α-MSH was partially reversed after AMPK inhibition with dorsomorphine. However, in the presence of dorsomorphine, low concentrations of α-MSH were still effective in reducing cellular cholesterol content and the concentration-response closely mirrored the profiles observed in p-JNK and p-ERK1/2 levels in α-MSH-treated HepG2 cells (i.e. U-shaped concentration-response). These results suggest that the α-MSH-mediated reduction in cellular cholesterol content relies on multiple pathways involving AMPK and MAPK signaling pathways. On the other hand, the cholesterol-lowering effect of the selective MC1-R agonist LD211 appeared to be completely dependent on AMPK phosphorylation, which might indicate that this synthetic agonist has a stronger signaling bias toward the AMPK pathway compared to α-MSH. Early in vitro studies have established that AMPK activation reduces cholesterol synthesis by inducing an inactivating phosphorylation of HMGCR (<xref ref-type="bibr" rid="bib9">Clarke and Hardie, 1990</xref>; <xref ref-type="bibr" rid="bib59">Steinberg and Kemp, 2009</xref>), while inhibition of AMPK increases cholesterol synthesis and cholesterol accumulation in the liver (<xref ref-type="bibr" rid="bib32">Loh et al., 2018</xref>). The link between MAPK signaling and cholesterol metabolism has not been widely studied but in vitro experiments using HepG2 cells have demonstrated that ERK1/2 activation phosphorylates SREBP2 (<xref ref-type="bibr" rid="bib28">Kotzka et al., 2004</xref>), which, in turn, is likely to induce e.g., <italic>HMGCR</italic> transcription. The role of hepatic JNK signaling is even less clear in this regard, but some evidence demonstrates that it contributes to diet-induced obesity and hepatic steatosis as well as to cholesterol and BA metabolism (<xref ref-type="bibr" rid="bib36">Manieri et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Manieri and Sabio, 2015</xref>; <xref ref-type="bibr" rid="bib63">Vernia et al., 2014</xref>). Against this background, it is plausible that both AMPK phosphorylation and inhibition of ERK1/2 and JNK signaling are involved in mediating the effects of α-MSH on cholesterol metabolism in hepatocytes. However, further experiments are warranted to dissect the exact signaling mechanism(s) of MC1-R activation that regulate cholesterol metabolism, e.g., to determine which G-protein subtype is involved in this regulation.</p><p>In conclusion, our study uncovers a novel role for MC1-R signaling in hepatic cholesterol and BA metabolism. Hepatocyte-specific MC1-R deficiency increased plasma cholesterol and TG concentration, disturbed BA metabolism, and led to signs of hepatic steatosis and fibrosis. Conversely, MC1-R activation in hepatocytes reduced cellular cholesterol content and increased LDL and HDL uptake, which are preventive mechanisms against hypercholesterolemia and the progression of NAFLD.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>All experiments were performed on adult (3–6 months) female mice. Mice were housed in groups of littermates on a 12 hr light/dark cycle. The numbers of mice studied in each experiment are given in the figure legends. Sample sizes were empirically determined based on previous experience with the experimental models. Where possible, experiments were conducted and analyzed by blinded researchers. Mice were maintained on a regular chow diet (# 2916 C, Teklad Global diet, Envigo) for the entire experimental duration unless otherwise stated. In each experiment, mice were euthanized <italic>via</italic> CO<sub>2</sub> asphyxiation, blood was withdrawn, and whole liver was excised and weighed. The experiments were approved by the local ethics committee (Animal Experiment Board in Finland, License Numbers: ESAVI/6280/04.10.07.2016 and ESAVI/1260/2020) and conducted in accordance with the institutional and national guidelines for the care and use of laboratory animals.</p><p>Eight-week-old C57BI/6 J mice (Janvier Labs, France) were fed a regular chow diet or Western-type diet (RD Western Diet, D12079B, Research Diets Inc, NJ, USA) for 12 weeks and used for the quantification of <italic>Mc1r</italic> mRNA and protein levels in the liver. In addition, hepatocyte-specific MC1-R knock-out mice (Mc1r LKO) were generated by breeding mice homozygous for a floxed <italic>Mc1r</italic> allele (<italic>Mc1r<sup>fl/fl</sup></italic> mice, the Jackson Laboratory, strain #029239) (<xref ref-type="bibr" rid="bib61">Takeo et al., 2016</xref>) with transgenic <italic>Alb<sup>Cre/+</sup></italic> mice (B6N.Cg-Speer6-ps1Tg(Alb-cre)21Mgn/J, the Jackson Laboratory, strain #018961) (<xref ref-type="bibr" rid="bib44">Postic et al., 1999</xref>). Age-matched <italic>Mc1r<sup>fl/fl</sup></italic> and <italic>Mc1r<sup>fl/+</sup> Alb<sup>Cre/+</sup></italic> mice were used as controls. Mice were weighed once a week during a monitoring period of 8 weeks (from 8 to 16 weeks of age). A separate cohort of 8-week-old <italic>Mc1r<sup>fl/fl</sup></italic> and Mc1r LKO mice were put on a Western-type diet (RD Western Diet, D12079B) for 12 weeks. Body composition was determined at the start and end of the 8- or 12 week monitoring period by quantitative nuclear magnetic resonance (NMR) scanning (EchoMRI-700, Echo Medical Systems, Houston, TX, USA). At the end of the experiment, genomic DNA samples from the liver were genotyped for the recombined allele using the following primers: ACC ACT GCG TGC TAT CCT G (<italic>Mc1r</italic> 5’forward), ACC CCT TCC CTT GAG GAG T (<italic>Mc1r</italic> 5’ reverse), and GAA CTC TGA GGT CAC TAT TTT CTG GAG A (<italic>Mc1r</italic> 3’ reverse).</p></sec><sec id="s4-2"><title>RNA sequencing data analysis</title><p>RNA-sequencing data deposited in the Gene Expression Omnibus (GSE120064) was used to study <italic>MC1R</italic> expression in human liver biopsy samples from patients diagnosed with NAFLD (n=51) or NASH (n=155) and healthy obese control cases (n=10) without any biochemical or histological evidence or NAFLD (<xref ref-type="bibr" rid="bib19">Govaere et al., 2020</xref>). Raw data were processed using FIMM-RNAseq data analysis workflow (version 2.0.7) (<xref ref-type="bibr" rid="bib25">Kangas et al., 2022</xref>). Raw reads were preprocessed using Trim Galore (version 0.6.6). Preprocessed reads were aligned to the reference genome GRCh39 (release 93) from Ensembl. Gene count data was produced using Subreads (version 2.0.1) (<xref ref-type="bibr" rid="bib31">Liao et al., 2013</xref>). Downstream data analysis was performed using R (version 4.2.0; <ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link>) package edgeR (version 3.40.2) (<xref ref-type="bibr" rid="bib53">Robinson et al., 2010</xref>). Low gene counts were removed using edgeR’s default parameters. Gene counts were normalized using the trimmed mean of M values (TMM) method and expressed as log2 RPKM (reads per kilobase of exon per million reads mapped) values.</p></sec><sec id="s4-3"><title>Cell culture</title><p>The HepG2 cell line was purchased from ATCC (American Type Culture Collection, Rockville, MD, USA; HB-8065; authenticated by STR profiling; mycoplasma contamination not detected) and maintained in DMEM (Dulbecco’s modified Eagle’s medium; Sigma-Aldrich) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; Gibco), 100 U/ml penicillin (Gibco), 100 µg/ml streptomycin (Gibco) at 37 °C in a humid atmosphere with 5% CO<sub>2</sub>. To study the regulation of MC1-R expression, HepG2 cells were serum-deprived (0.5% FBS) for 16 h and thereafter treated with 200 µg/ml LDL (CliniSciences), 10 µM atorvastatin (Sigma-Aldrich) or 500 µM palmitic acid (Sigma-Aldrich) for 1, 3, 6, or 24 hr. To study the effects of melanocortin system activation, cells were seeded on 12- or 24-well plates and treated with the non-selective MC-R agonist α-MSH (abcam, # ab120189) or the selective MC1-R agonist LD211 (<xref ref-type="bibr" rid="bib14">Doedens et al., 2010</xref>) (compound 28 in the original publication), as indicated in the figure legends.</p></sec><sec id="s4-4"><title>Histology, immunohistochemistry, and immunofluorescence staining</title><p>A transverse piece of the left lobe was fixed in 10% formalin overnight followed by embedding in paraffin. Four µm-thick serial sections were stained with hematoxylin and eosin (H&amp;E), Picrosirius Red (abcam, # ab150681), or used for MC1-R immunohistochemistry as previously described (<xref ref-type="bibr" rid="bib51">Rinne et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Rinne et al., 2015</xref>). Briefly, sections were incubated in 10 mM sodium citrate buffer (pH 6) for 20 min in a pressure cooker for antigen retrieval. Thereafter, sections were quenched in 1% H<sub>2</sub>O<sub>2</sub> for 10 min and blocked in 5% normal horse serum containing 1% BSA. After blocking, sections were incubated overnight with a primary antibody against MC1-R (Elabscience, Texas, USA, # E-AB-15765) followed by biotinylated horseradish peroxidase-conjugated secondary antibody incubation and detection with diaminobenzidine (ABC kit, Vector Labs, Burlingame, USA). For isotype control, a consecutive heart section was treated similarly except that the primary MC1-R antibody was replaced by purified normal rabbit IgG (Novus Biologicals, Littleton, CO, USA, # NB810-56910). For immunofluorescence, liver sections were incubated overnight with antibodies against MC1-R (Elabscience) and serum albumin (Bioss Antibodies, # BSM-0945M), cytokeratin 19 (CK-19, Novus Biologicals, # NBP2-44827), CD31 (R&amp;D Systems, # AF3628), or Mac-2 (Cedarlane labs, # CL8942AP) followed by detection with fluorochrome-conjugated secondary antibodies (anti-rabbit Alexa Fluor 647 and anti-mouse, anti-rat or anti-goat Alexa Fluor 488, Invitrogen). To visualize hepatic lipid content, a transverse piece of the left liver lobe was embedded in O.C.T. compound (Tissue-Tek), cryosectioned and stained with Oil Red O. Sections were counterstained with hematoxylin (CarlRoth) or DAPI (Fluoroshield mounting medium, abcam), cover-slipped and then scanned with Pannoramic 250 or Pannoramic Midi digital slide scanner (3DHISTECH Kft, Budapest, Hungary).</p></sec><sec id="s4-5"><title>RNA isolation, cDNA synthesis, and quantitative RT-PCR</title><p>HepG2 cell samples were collected into QIAzol Lysis Reagent and total RNA was extracted using Direct-zol RNA Miniprep (Zymo Research, CA, USA). Liver samples were first homogenized in QIAzol Lysis Reagent (Qiagen) using the Qiagen TissueLyser LT Bead Mill (QIAGEN, Venlo, Netherlands). Total RNA from each sample was extracted and reverse-transcribed to cDNA with PrimeScript RT reagent kit (Takara Clontech) according to the manufacturer’s instructions. The RNA quality and concentration were evaluated by Nanodrop. Quantitative real-time polymerase chain reaction (RT-PCR) was performed using SYBR Green protocols (Kapa Biosystems, MA, USA) on a real-time PCR detection system (Applied Biosystems 7300 Real-Time PCR system). Each sample was run in duplicate. Target gene expression was normalized to the geometric mean of two housekeeping genes (β-actin and ribosomal protein S29 or GAPDH) using the delta-Ct method and results are presented as relative transcript levels (2<sup>-ΔΔCt</sup>). Primer sequences are presented in <xref ref-type="table" rid="table1 table2">Tables 1 and 2</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Quantitative RT-PCR primers for mouse genes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene nameAccession number</th><th align="left" valign="bottom">5’–3’ primer sequence</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold><italic>Actb</italic></bold><break/>NM_007393.5</td><td align="left" valign="bottom">Forward: tccatcatgaagtgtgacgt<break/>Reverse: gagcaatgatcttgatcttca</td></tr><tr><td align="left" valign="bottom"><bold><italic>Akr1d1</italic></bold><break/>NM_145364.2</td><td align="left" valign="bottom">Forward: gaaaagatagcagaagggaaggt<break/>Reverse: gggacatgctctgtattccataa</td></tr><tr><td align="left" valign="bottom"><bold><italic>Bsep</italic></bold><break/>NM_021022.3</td><td align="left" valign="bottom">Forward: aagctacatctgccttagacacagaa<break/>Reverse: caatacaggtccgaccctctct</td></tr><tr><td align="left" valign="bottom"><bold><italic>Ccl2</italic></bold><break/>NM_011333.3</td><td align="left" valign="bottom">Forward: aggtccctgtcatgcttctg<break/>Reverse: aaggcatcacagtccgagtc</td></tr><tr><td align="left" valign="bottom"><bold><italic>Col1a1</italic></bold><break/>NM_007742.4</td><td align="left" valign="bottom">Forward: gctcctcttaggggccact<break/>Reverse: ccacgtctcaccattgggg</td></tr><tr><td align="left" valign="bottom"><bold><italic>Cyp7a1</italic></bold><break/>NM_007824.2</td><td align="left" valign="bottom">Forward: gatcctctgggcatctcaag<break/>Reverse: agaggctgctttcattgctt</td></tr><tr><td align="left" valign="bottom"><bold><italic>Cyp7b1</italic></bold><break/>NM_007825.4</td><td align="left" valign="bottom">Forward: gaaaactcttcaaaggcaacatgg<break/>Reverse: actggaaagggttcagaacaaatg</td></tr><tr><td align="left" valign="bottom"><bold><italic>Cyp8b1</italic></bold><break/>NM_010012.3</td><td align="left" valign="bottom">Forward: gccttcaagtatgatcggttcct<break/>Reverse: gatcttcttgcccgacttgtaga</td></tr><tr><td align="left" valign="bottom"><bold><italic>Cyp27a1</italic></bold><break/>NM_024264.5</td><td align="left" valign="bottom">Forward: gcctcacctatgggatcttca<break/>Reverse: tcaaagcctgacgcagatg</td></tr><tr><td align="left" valign="bottom"><bold><italic>Fxr</italic></bold><break/>NM_001163700.1</td><td align="left" valign="bottom">Forward: tccggacattcaaccatcac<break/>Reverse: tcactgcacatcccagatctc</td></tr><tr><td align="left" valign="bottom"><bold><italic>Hnf4a</italic></bold><break/>NM_008261.3</td><td align="left" valign="bottom">Forward: accaagaggtccatggtgttt<break/>Reverse: gtgccgagggacgatgtag</td></tr><tr><td align="left" valign="bottom"><bold><italic>Hsd3b7</italic></bold><break/>NM_133943.2</td><td align="left" valign="bottom">Forward: gggagctgcgtgtctttga<break/>Reverse: gtggatggtctttggactggc</td></tr><tr><td align="left" valign="bottom"><bold><italic>Il1b</italic></bold><break/>NM_008361.4</td><td align="left" valign="bottom">Forward: tgtaatgaaagacggcacacc<break/>Reverse: tcttctttgggtattgcttgg</td></tr><tr><td align="left" valign="bottom"><bold><italic>Il6</italic></bold><break/>NM_031168.2</td><td align="left" valign="bottom">Forward: ggccttccctacttcacaag<break/>Reverse: atttccacgatttcccagag</td></tr><tr><td align="left" valign="bottom"><bold><italic>Lrh1</italic></bold><break/>NM_030676.3</td><td align="left" valign="bottom">Forward: tgggaaggaagggacaatctt<break/>Reverse: cgagactcaggaggttgttgaa</td></tr><tr><td align="left" valign="bottom"><bold><italic>Abcc3 (Mrp3)</italic></bold><break/>NM_029600.4</td><td align="left" valign="bottom">Forward: ctgggtcccctgcatctac<break/>Reverse: gccgtcttgagcctggataac</td></tr><tr><td align="left" valign="bottom"><bold><italic>Abcc4 (Mrp4)</italic></bold><break/>NM_001163676.1</td><td align="left" valign="bottom">Forward: ggcactccggttaagtaactc<break/>Reverse: tgtcacttggtcgaatttgttca</td></tr><tr><td align="left" valign="bottom"><bold><italic>Ntcp</italic></bold><break/>NM_011387.2</td><td align="left" valign="bottom">Forward: gaagtccaaaaggccacactatgt<break/>Reverse: acagccacagagagggagaaag</td></tr><tr><td align="left" valign="bottom"><bold>Gene name</bold><break/>Accession number</td><td align="left" valign="bottom"><bold>5’–3’ primer sequence</bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>Slc51a (Osta)</italic></bold><break/>NM_145932.3</td><td align="left" valign="bottom">Forward: aggcaggactcatatcaaacttg<break/>Reverse: tgagggctatgtccactggg</td></tr><tr><td align="left" valign="bottom"><bold><italic>S29</italic></bold><break/>NM_009093.2</td><td align="left" valign="bottom">Forward: atgggtcaccagcagctcta<break/>Reverse: agcctatgtccttcgcgtact</td></tr><tr><td align="left" valign="bottom"><bold><italic>Nr0b2(Shp)</italic></bold><break/>NM_011850.3</td><td align="left" valign="bottom">Forward: tgggtcccaaggagtatgc<break/>Reverse: gctccaagacttcacacagtg</td></tr><tr><td align="left" valign="bottom"><bold><italic>Stard1</italic></bold><break/>NM_011485.5</td><td align="left" valign="bottom">Forward: atgttcctcgctacgttcaag<break/>Reverse: cccagtgctctccagttgag</td></tr><tr><td align="left" valign="bottom"><bold><italic>Tgfb1</italic></bold><break/>NM_011577.2</td><td align="left" valign="bottom">Forward: ccgcaacaacgccatctatg<break/>Reverse: cccgaatgtctgacgtattgaag</td></tr><tr><td align="left" valign="bottom"><bold><italic>Tnf</italic></bold><break/>NM_013693.3</td><td align="left" valign="bottom">Forward: ctgaacttcggggtgatcgg<break/>Reverse: ggcttgtcactcgaattttgaga</td></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Quantitative RT-PCR primers for human genes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene nameAccession number</th><th align="left" valign="bottom">5’–3’ primer sequence</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold><italic>ACTA1</italic></bold><break/>NM_001100.4</td><td align="left" valign="bottom">Forward: aggtcatcaccatcggcaacga<break/>Reverse: gctgttgtaggtggtctcgtga</td></tr><tr><td align="left" valign="bottom"><bold><italic>ACTA2</italic></bold><break/>NM_001613.4</td><td align="left" valign="bottom">Forward: ctatgcctctggacgcacaact<break/>Reverse: cagatccagacgcatgatggca</td></tr><tr><td align="left" valign="bottom"><bold><italic>ACTB</italic></bold><break/>NM_001101.5</td><td align="left" valign="bottom">Forward: caccattggcaatgagcggttc<break/>Reverse: aggtctttgcggatgtccacgt</td></tr><tr><td align="left" valign="bottom"><bold><italic>COL1A1</italic></bold><break/>NM_000088.4</td><td align="left" valign="bottom">Forward: gagggccaagacgaagacatc<break/>Reverse: cagatcacgtcatcgcacaac</td></tr><tr><td align="left" valign="bottom"><bold><italic>GAPDH</italic></bold><break/>NM_002046.7</td><td align="left" valign="bottom">Forward: tcaaggctgagaacgggaag<break/>Reverse: cgccccacttgattttggag</td></tr><tr><td align="left" valign="bottom"><bold><italic>IL6</italic></bold><break/>NM_00600.5</td><td align="left" valign="bottom">Forward: gatgagtacaaaagtcctgatcca<break/>Reverse: ctgcagccactggttctgt</td></tr><tr><td align="left" valign="bottom"><bold><italic>LDLR</italic></bold><break/>NM_000527.5</td><td align="left" valign="bottom">Forward: ccacggtggagatagtgaca<break/>Reverse: ctcacgctactgggcttctt</td></tr><tr><td align="left" valign="bottom"><bold><italic>SCARB1</italic></bold><break/>NM_005505.5</td><td align="left" valign="bottom">Forward: ctggcagaagcggtgact<break/>Reverse: cagagcagttcatggggatt</td></tr><tr><td align="left" valign="bottom"><bold><italic>TGFB1</italic></bold><break/>NM_000660.7</td><td align="left" valign="bottom">Forward: tacctgaacccgtgttgctctc<break/>Reverse: gttgctgaggtatcgccaggaa</td></tr><tr><td align="left" valign="bottom"><bold><italic>TNF</italic></bold><break/>NM_000594.4</td><td align="left" valign="bottom">Forward: cctctctctaatcagccctctg<break/>Reverse: gaggacctgggagtagatgag</td></tr></tbody></table></table-wrap></sec><sec id="s4-6"><title>Immunoblotting</title><p>Liver and HepG2 samples were lysed in RIPA buffer (50 mM NaCl, 1% Triton X-100, 0.5% Sodium deoxycholate, 0.1% SDS, pH 8.0) supplemented with protease and phosphatase inhibitor cocktail (ThermoFisher, #A32961). Liver samples were additionally homogenized using the Qiagen TissueLyser LT Bead. Equal amounts (30 µg) of total protein were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes (GE Healthcare). After blocking with Tris-Buffered Saline (Sigma-Aldrich) containing 0.1% Tween 20 detergent (Sigma-Aldrich) and 5% skimmed milk (Carl Roth) for 1 hr at room temperature (RT), membranes were incubated with specific primary antibodies for MC1-R (Alomone Labs, #AMR-025), LDLR (Novus Biologicals, Littleton, CO, USA, #NBP1-06709), SR-BI (NovusBio, #NB400-104), SREBP2 (Novus Biologicals, #NB100-74543), HMGCR (Novus Biologicals, #NBP2-66888), DHCR7 (abcam, #ab103296), MRP4 (Cell Signaling Tech, Frankfurt, DE, #12857), StAR (Cell Signaling Tech, #8449), CYP8B1 (St John’s Laboratory Ltd, #STJ92607), phospho-AMPKα (Cell Signaling Tech, #2535), and AMPKα (Cell Signaling Tech, #2532) over-night at +4 °C. Next day, membranes were washed and incubated with Horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling Tech) for 1 hr at RT. Proteins were visualized using a chemiluminescence (ECL) kit (Millipore, MA, USA). Target protein expression was normalized to β-actin (Sigma-Aldrich, #2066) or vinculin (Bio-Rad, #MCA465GA) to correct for loading, and band densities were analyzed using ImageJ software (NIH, Bethesda, MD, USA).</p></sec><sec id="s4-7"><title>Plasma and liver extract analyses</title><p>Plasma samples were obtained from EDTA-anticoagulated whole blood after centrifugation. Plasma total cholesterol and triglyceride concentrations were determined using enzymatic colorimetric assays (CHOD-PAP and GPO-PAP, mtiDiagnostics, Idstein, Germany) according to the manufacturer’s protocols. For the determination of hepatic lipid content, liver samples (~100 mg) were homogenized in 500 µl of PBS with 0.1% NP-40 (Abcam) using TissueLyser and then centrifuged to remove insoluble components (<xref ref-type="bibr" rid="bib41">Nuutinen et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Rinne et al., 2018</xref>). Cholesterol and triglycerides concentrations were quantified in the liver homogenates using CHOD-PAP and GPO-PAP reagents.</p></sec><sec id="s4-8"><title>Bile acid measurements</title><p>Bile acids (BA) were measured in plasma, liver, and fecal samples. BAs were extracted and analyzed by an ultra-high-performance liquid chromatography tandem-mass spectrometry method (UHPLC-MS/MS) as previously described (<xref ref-type="bibr" rid="bib23">Jäntti et al., 2014</xref>). The order of the samples was randomized before sample preparation. The BAs analysed were Litocholic acid (LCA), 12-oxo-litocholic acid (12-oxo-LCA), Chenodeoxycholic acid (CDCA), Deoxycholic acid (DCA), Hyodeoxycholic acid (HDCA), Ursodeoxycholic acid (UDCA), Dihydroxycholestanoic acid (DHCA), 7-oxo-deoxycholic acid (7-oxo-DCA), 7-oxo-hyocholic acid (7-oxo-HCA), Hyocholic acid(HCA), β-Muricholic acid (β-MCA), Cholic acid (CA), ω/α-Muricholic acid (ω/α-MCA), Glycolitocholic acid (GLCA), Glycochenodeoxycholic acid (GCDCA), Glycodeoxycholic acid (GDCA), Glycohyodeoxycholic acid (GHDCA), Glycoursodeoxycholic acid (GUDCA), Glycodehydrocholic acid (GDHCA), Glycocholic acid (GCA), Glycohyocholic acid (GHCA), Taurolitocholic acid (TLCA), Taurochenodeoxycholic acid (TCDCA), Taurodeoxycholic acid (TDCA), Taurohyodeoxycholic acid (THDCA), Tauroursodeoxycholic acid (TUDCA), Taurodehydrocholic acid (TDHCA), Tauro-α-muricholic acid (TαMCA), Tauro-β-muricholic acid (TβMCA), Taurocholic acid (TCA), Trihydroxycholestanoic acid (THCA), and Tauro-ω-muricholic acid (TωMCA).</p><p>For plasma sample analysis, BAs were extracted by adding 20 µl plasma to 200 µl crash solvent methanol containing 25 ppb LCA-d4 and 2.5 ppb each of the internal standards (TCA-d4, GUDCA-d4, GCA-d4, CA-d4, UDCA-d4, GCDCA-d4, CDCA-d4, DCA-d4, and GLCA-d4) and filtering them using a Supelco protein precipitation filter plate. A 170 uL aliquot of the supernatant was dried under a gentle flow of nitrogen and resuspended using 20 µL resuspension solution (Methanol:water (40:60) with 5 ppb Perfluoro-n-[13C9]nonanoic acid as in injection standard). Blank samples were prepared by pipetting 200 µl crash solvent into a vial, then drying and resuspending them the same way as the other samples. Calibration curves were prepared by pipetting 20 µl of standard dilution into vials, adding 200 µL crash solution, and drying and resuspending them in the same way as the other samples. The concentrations of the standard dilutions were between 0.0025 and 600 ppb.</p><p>Aliquots of 25 mg of liver were powdered using dry ice under a glass plate and transferred to a plastic tube. Water (100 µl) was added and the sample was sonicated for 30 s. For protein precipitation and extraction, 300 ul of acetonitrile was added and the samples were filtered using a Supelco protein precipitation filter plate. A 255 ul aliquot of the supernatant was dried under a gentle flow of nitrogen and resuspended using a 20 µl resuspension solution.</p><p>Feces were collected over 48 hr from individually housed mice. All fecal samples were freeze-dried prior to extraction to determine the dry weight and 20 µl of water was added for each mg of dry weight in the sample. The samples were homogenized by adding homogenizer beads, freezing samples to at least –70 °C, and homogenizing them for 5 min using a bead beater. BAs were extracted by adding 40 µl fecal homogenate to 400 µl crash solvent (methanol containing 62, 5 ppb each of the internal standards) and filtering them using a Supelco protein precipitation filter plate. The samples were dried and resuspended the same way as serum samples. QCs, blanks, and calibration curves were prepared similarly to plasma samples.</p><p>The LC separation was performed on a Sciex Exion AD 30 (AB Sciex Inc, Framingham, MA) LC system consisting of a binary pump, an autosampler set to 15 °C, and a column oven set to 35 °C. A waters Aquity UPLC HSS T3 (1.8 µm, 2.1 × 100 mm) column with a precolumn with the same material. Eluent A was 0.1% formic acid in water and eluent B was 0.1% formic acid in methanol. The gradient started from 15% B and increased to 30% B over 1 min. The gradient further increased to 70% B over 15 min. The gradient was further increased to 100% over 2 min. The gradient was held at 100% B for 4 min then decreased to 15% B over 0.1 min and re-equilibrated for 7.5 min. The flow rate was 0.5 mL/min and the injection volume was 5 µL.</p><p>The mass spectrometer used for this method was a Sciex 5500 QTrap mass spectrometer operating in scheduled multiple reaction monitoring mode in negative mode. The ion source gas 1 and 2 were both 40 psi. The curtain gas was 25 psi, the CAD gas was 12 and the temperature was 650 °C. The spray voltage was 4500 V. Data processing was performed on Sciex MultiQuant.</p></sec><sec id="s4-9"><title>Filipin staining of cellular free cholesterol</title><p>HepG2 cells were seeded (40,000 cells/well) on 96-well plates (PhenoPlate, PerkinElmer) and grown until the cells reached 70% confluency. Thereafter, cells were first serum-deprived (0.5% FBS) for 16 hr, and then treated with either α-MSH or LD211 for 24 hr. After the treatment, cells were washed with PBS and fixed with 4% paraformaldehyde (Sigma-Aldrich) for 15 min at room temperature. Cells were subsequently washed with PBS and incubated with 1.5 mg/ml glycine (Sigma-Aldrich, 10 min at RT) to quench unreacted paraformaldehyde followed by washing with PBS. Cells were stained with 50 ug/ml of Filipin (Sigma-Aldrich, #F9765) for 1 hr at 37 °C and washed with PBS. Fluorescence signal was measured with EnSight Multimode Plate Reader (PerkinElmer) with the 360 nm excitation and 480 emission wavelengths.</p></sec><sec id="s4-10"><title>LDL and HDL uptake assay</title><p>HepG2 cells were seeded (40,000 cells/well) on 96-well plates (PhenoPlate, PerkinElmer), serum-deprived (0.5% FBS) for 16 hr and then treated with α-MSH or LD211 for 18 hr at 37 °C. After the treatment, cells were washed with PBS and incubated with fluorescently-labeled HDL (Dil-HDL, 20 µg/ml, CliniSciences) or LDL (Dil-LDL, 10 µg/ml, CliniSciences) for 4 hr at 37 °C. After the incubation, cells were again washed with PBS and the fluorescence signal was measured with EnSight Multimode Plate Reader (PerkinElmer) with the 549 nm excitation and 565 emission wavelengths and normalized against cell confluency.</p></sec><sec id="s4-11"><title>Flow cytometric analysis of cell surface LDLR expression</title><p>HepG2 cells were treated as indicated in the figure legends, washed with PBS, and detached using EDTA. To quantify the expression of LDLR on the cell surface, HepG2 cells were stained with PE-conjugated anti-human LDLR antibody (clone C7, BD Biosciences) and then analyzed with LSR Fortessa (BD Biosciences) and FlowJo software (FlowJo, LLC, Ashland, USA).</p></sec><sec id="s4-12"><title>Cyclic AMP determination</title><p>To measure intracellular cAMP concentrations, HepG2 cells were pretreated with 3-isobutyl-1-methylxanthine (0.1 mM, IBMX, Sigma-Aldrich) for 30 min and then stimulated with α-MSH or the selective MC1-R agonist LD211 (0.1 nM, 10 nM or 1 µM) for 30 min. Cells were thereafter lysed with 0.1 M HCl and assayed for cAMP levels with a commercial kit (Cyclic AMP Select ELISA kit, Cayman Chemical, #501040) according to the manufacturer’s instructions. Results were normalized against total protein concentrations (Pierce BCA Protein Assay Kit, Thermo Fisher) and expressed as a percentage of control samples that were left untreated.</p></sec><sec id="s4-13"><title>Enzyme-linked immunosorbent assays (ELISA) of phosphorylated ERK1/2 and JNK</title><p>HepG2 cells were stimulated with α-MSH or the selective MC1-R agonist LD211 as indicated in the figure legends. Cells were thereafter lysed with Lysis Buffer #6 (R&amp;D Systems) and assayed for the expression levels of phospho-ERK1 (T202/Y204)/ERK2 (T185/Y187) and phospho-JNK (T183/Y185 for JNK1/2 and T221/Y223 for JNK3) with commercial kits (DuoSet IC ELISA, R&amp;D Systems, # DYC1018B and # DYC1387B) according to manufacturer’s instructions. Results were normalized against total protein concentrations (Pierce BCA Protein Assay Kit, ThermoFisher).</p></sec><sec id="s4-14"><title>Statistics</title><p>All experiments were performed at least three independent times. Statistical analyses were performed with GraphPad Prism 9 software (La Jolla, CA, USA). Statistical significance between the experimental groups was determined by two-tailed, unpaired Student’s t-test or one-way or two-way ANOVA followed by Dunnet <italic>post hoc</italic> tests. The D’Agostino and Pearson omnibus normality test method was utilized to check the normality of the data. Possible outliers in the data sets were identified using the regression and outlier removal (ROUT) method of Q-level of 1%. Data are expressed as mean ± standard error of the mean (SEM). Results were considered significant for p&lt;0.05.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con6"><p>Resources, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The animal experiments were approved by the local ethics committee (Animal Experiment Board in Finland, License Numbers: ESAVI/6280/04.10.07.2016 and ESAVI/1260/2020) and conducted in accordance with the institutional and national guidelines for the care and use of laboratory animals.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84782-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file. Source Data files have been provided for Main Figures and Supplementary Figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Sanna Bastman, Salla Juhantalo, and Johanna Jukkala for their excellent technical support. The histological methods were performed by the Histology core facility of the Institute of Biomedicine, University of Turku, Finland. BA measurements were performed at the Turku Metabolomics Centre (Turku Bioscience Centre, Turku, Finland) with the support of Biocenter Finland. Turku Center for Disease Modeling, TCDM, Turku, Finland, (<ext-link ext-link-type="uri" xlink:href="https://www.tcdm.fi/">https://www.tcdm.fi/</ext-link>), a member of Biocenter Finland, is acknowledged for setting up the genotyping protocol for Mc1r LKO mice. This work was supported by the Academy of Finland (grant 315351 to PR); the Sigrid Jusélius Foundation (to PR); the Finnish Cultural Foundation (to PR), the Finnish Foundation for Cardiovascular Research (to ES and PR); and the National Institutes of Health (grant GM-104080 to MC).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becher</surname><given-names>E</given-names></name><name><surname>Mahnke</surname><given-names>K</given-names></name><name><surname>Brzoska</surname><given-names>T</given-names></name><name><surname>Kalden</surname><given-names>DH</given-names></name><name><surname>Grabbe</surname><given-names>S</given-names></name><name><surname>Luger</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Human peripheral blood-derived dendritic cells express functional melanocortin receptor MC-1R</article-title><source>Annals of the New York Academy of Sciences</source><volume>885</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb08676.x</pub-id><pub-id pub-id-type="pmid">10816652</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böhm</surname><given-names>M</given-names></name><name><surname>Stegemann</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bleomycin-induced fibrosis in MC1 signalling-deficient C57BL/6J-Mc1r(e/e) mice further supports a modulating role for melanocortins in collagen synthesis of the skin</article-title><source>Experimental Dermatology</source><volume>23</volume><fpage>431</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1111/exd.12409</pub-id><pub-id pub-id-type="pmid">24698097</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burg</surname><given-names>JS</given-names></name><name><surname>Espenshade</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation of HMG-CoA reductase in mammals and yeast</article-title><source>Progress in Lipid Research</source><volume>50</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2011.07.002</pub-id><pub-id pub-id-type="pmid">21801748</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The global epidemic of obesity: an overview</article-title><source>Epidemiologic Reviews</source><volume>29</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/epirev/mxm012</pub-id><pub-id pub-id-type="pmid">17569676</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>F</given-names></name><name><surname>Fernández</surname><given-names>A</given-names></name><name><surname>De Lacy</surname><given-names>AM</given-names></name><name><surname>Fernández-Checa</surname><given-names>JC</given-names></name><name><surname>Caballería</surname><given-names>J</given-names></name><name><surname>García-Ruiz</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH</article-title><source>Journal of Hepatology</source><volume>50</volume><fpage>789</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2008.12.016</pub-id><pub-id pub-id-type="pmid">19231010</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catania</surname><given-names>A</given-names></name><name><surname>Rajora</surname><given-names>N</given-names></name><name><surname>Capsoni</surname><given-names>F</given-names></name><name><surname>Minonzio</surname><given-names>F</given-names></name><name><surname>Star</surname><given-names>RA</given-names></name><name><surname>Lipton</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro</article-title><source>Peptides</source><volume>17</volume><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/0196-9781(96)00037-x</pub-id><pub-id pub-id-type="pmid">8804079</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catania</surname><given-names>A</given-names></name><name><surname>Gatti</surname><given-names>S</given-names></name><name><surname>Colombo</surname><given-names>G</given-names></name><name><surname>Lipton</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Targeting melanocortin receptors as a novel strategy to control inflammation</article-title><source>Pharmacological Reviews</source><volume>56</volume><fpage>1</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1124/pr.56.1.1</pub-id><pub-id pub-id-type="pmid">15001661</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>JYL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms</article-title><source>Journal of Hepatology</source><volume>40</volume><fpage>539</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2003.11.006</pub-id><pub-id pub-id-type="pmid">15123373</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>PR</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver</article-title><source>The EMBO Journal</source><volume>9</volume><fpage>2439</fpage><lpage>2446</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb07420.x</pub-id><pub-id pub-id-type="pmid">2369897</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conde de la Rosa</surname><given-names>L</given-names></name><name><surname>Garcia-Ruiz</surname><given-names>C</given-names></name><name><surname>Vallejo</surname><given-names>C</given-names></name><name><surname>Baulies</surname><given-names>A</given-names></name><name><surname>Nuñez</surname><given-names>S</given-names></name><name><surname>Monte</surname><given-names>MJ</given-names></name><name><surname>Marin</surname><given-names>JJG</given-names></name><name><surname>Baila-Rueda</surname><given-names>L</given-names></name><name><surname>Cenarro</surname><given-names>A</given-names></name><name><surname>Civeira</surname><given-names>F</given-names></name><name><surname>Fuster</surname><given-names>J</given-names></name><name><surname>Garcia-Valdecasas</surname><given-names>JC</given-names></name><name><surname>Ferrer</surname><given-names>J</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Ribas</surname><given-names>V</given-names></name><name><surname>Fernandez-Checa</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway</article-title><source>Journal of Hepatology</source><volume>74</volume><fpage>1429</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.01.028</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crosignani</surname><given-names>A</given-names></name><name><surname>Del Puppo</surname><given-names>M</given-names></name><name><surname>Longo</surname><given-names>M</given-names></name><name><surname>De Fabiani</surname><given-names>E</given-names></name><name><surname>Caruso</surname><given-names>D</given-names></name><name><surname>Zuin</surname><given-names>M</given-names></name><name><surname>Podda</surname><given-names>M</given-names></name><name><surname>Javitt</surname><given-names>NB</given-names></name><name><surname>Kienle</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Changes in classic and alternative pathways of bile acid synthesis in chronic liver disease</article-title><source>Clinica Chimica Acta; International Journal of Clinical Chemistry</source><volume>382</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2007.03.025</pub-id><pub-id pub-id-type="pmid">17482152</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>PA</given-names></name><name><surname>Lan</surname><given-names>T</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Bile acid transporters</article-title><source>Journal of Lipid Research</source><volume>50</volume><fpage>2340</fpage><lpage>2357</lpage><pub-id pub-id-type="doi">10.1194/jlr.R900012-JLR200</pub-id><pub-id pub-id-type="pmid">19498215</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>AM</given-names></name><name><surname>Day</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis</article-title><source>The New England Journal of Medicine</source><volume>377</volume><fpage>2063</fpage><lpage>2072</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1503519</pub-id><pub-id pub-id-type="pmid">29166236</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doedens</surname><given-names>L</given-names></name><name><surname>Opperer</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>JG</given-names></name><name><surname>Dedek</surname><given-names>M</given-names></name><name><surname>Palmer</surname><given-names>E</given-names></name><name><surname>Hruby</surname><given-names>VJ</given-names></name><name><surname>Kessler</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies</article-title><source>Journal of the American Chemical Society</source><volume>132</volume><fpage>8115</fpage><lpage>8128</lpage><pub-id pub-id-type="doi">10.1021/ja101428m</pub-id><pub-id pub-id-type="pmid">20496895</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erickson</surname><given-names>SK</given-names></name><name><surname>Lear</surname><given-names>SR</given-names></name><name><surname>Deane</surname><given-names>S</given-names></name><name><surname>Dubrac</surname><given-names>S</given-names></name><name><surname>Huling</surname><given-names>SL</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Bollineni</surname><given-names>JS</given-names></name><name><surname>Shefer</surname><given-names>S</given-names></name><name><surname>Hyogo</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>DE</given-names></name><name><surname>Shneider</surname><given-names>B</given-names></name><name><surname>Sehayek</surname><given-names>E</given-names></name><name><surname>Ananthanarayanan</surname><given-names>M</given-names></name><name><surname>Balasubramaniyan</surname><given-names>N</given-names></name><name><surname>Suchy</surname><given-names>FJ</given-names></name><name><surname>Batta</surname><given-names>AK</given-names></name><name><surname>Salen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice</article-title><source>Journal of Lipid Research</source><volume>44</volume><fpage>1001</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1194/jlr.M200489-JLR200</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Neuschwander-Tetri</surname><given-names>BA</given-names></name><name><surname>Rinella</surname><given-names>M</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of NAFLD development and therapeutic strategies</article-title><source>Nature Medicine</source><volume>24</volume><fpage>908</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0104-9</pub-id><pub-id pub-id-type="pmid">29967350</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gantz</surname><given-names>I</given-names></name><name><surname>Fong</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The melanocortin system</article-title><source>American Journal of Physiology. Endocrinology and Metabolism</source><volume>284</volume><fpage>E468</fpage><lpage>E474</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00434.2002</pub-id><pub-id pub-id-type="pmid">12556347</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatti</surname><given-names>S</given-names></name><name><surname>Colombo</surname><given-names>G</given-names></name><name><surname>Turcatti</surname><given-names>F</given-names></name><name><surname>Lonati</surname><given-names>C</given-names></name><name><surname>Sordi</surname><given-names>A</given-names></name><name><surname>Bonino</surname><given-names>F</given-names></name><name><surname>Lipton</surname><given-names>JM</given-names></name><name><surname>Catania</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Reduced expression of the melanocortin-1 receptor in human liver during brain death</article-title><source>Neuroimmunomodulation</source><volume>13</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1159/000094513</pub-id><pub-id pub-id-type="pmid">16864968</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govaere</surname><given-names>O</given-names></name><name><surname>Cockell</surname><given-names>S</given-names></name><name><surname>Tiniakos</surname><given-names>D</given-names></name><name><surname>Queen</surname><given-names>R</given-names></name><name><surname>Younes</surname><given-names>R</given-names></name><name><surname>Vacca</surname><given-names>M</given-names></name><name><surname>Alexander</surname><given-names>L</given-names></name><name><surname>Ravaioli</surname><given-names>F</given-names></name><name><surname>Palmer</surname><given-names>J</given-names></name><name><surname>Petta</surname><given-names>S</given-names></name><name><surname>Boursier</surname><given-names>J</given-names></name><name><surname>Rosso</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Wonders</surname><given-names>K</given-names></name><name><surname>Day</surname><given-names>CP</given-names></name><name><surname>Ekstedt</surname><given-names>M</given-names></name><name><surname>Orešič</surname><given-names>M</given-names></name><name><surname>Darlay</surname><given-names>R</given-names></name><name><surname>Cordell</surname><given-names>HJ</given-names></name><name><surname>Marra</surname><given-names>F</given-names></name><name><surname>Vidal-Puig</surname><given-names>A</given-names></name><name><surname>Bedossa</surname><given-names>P</given-names></name><name><surname>Schattenberg</surname><given-names>JM</given-names></name><name><surname>Clément</surname><given-names>K</given-names></name><name><surname>Allison</surname><given-names>M</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Ratziu</surname><given-names>V</given-names></name><name><surname>Daly</surname><given-names>AK</given-names></name><name><surname>Anstee</surname><given-names>QM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eaba4448</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aba4448</pub-id><pub-id pub-id-type="pmid">33268509</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Obesity, metabolic syndrome, and cardiovascular disease</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>89</volume><fpage>2595</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-0372</pub-id><pub-id pub-id-type="pmid">15181029</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmeyer</surname><given-names>M</given-names></name><name><surname>Scholzen</surname><given-names>T</given-names></name><name><surname>Becher</surname><given-names>E</given-names></name><name><surname>Bhardwaj</surname><given-names>RS</given-names></name><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Luger</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone</article-title><source>Journal of Immunology</source><volume>159</volume><fpage>1930</fpage><lpage>1937</lpage><pub-id pub-id-type="pmid">9257858</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Yokoyama</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Briggs</surname><given-names>MR</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element</article-title><source>PNAS</source><volume>90</volume><fpage>11603</fpage><lpage>11607</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.24.11603</pub-id><pub-id pub-id-type="pmid">7903453</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jäntti</surname><given-names>SE</given-names></name><name><surname>Kivilompolo</surname><given-names>M</given-names></name><name><surname>Ohrnberg</surname><given-names>L</given-names></name><name><surname>Pietiläinen</surname><given-names>KH</given-names></name><name><surname>Nygren</surname><given-names>H</given-names></name><name><surname>Orešič</surname><given-names>M</given-names></name><name><surname>Hyötyläinen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantitative profiling of bile acids in blood, adipose tissue, intestine, and gall bladder samples using ultra high performance liquid chromatography-tandem mass spectrometry</article-title><source>Analytical and Bioanalytical Chemistry</source><volume>406</volume><fpage>7799</fpage><lpage>7815</lpage><pub-id pub-id-type="doi">10.1007/s00216-014-8230-9</pub-id><pub-id pub-id-type="pmid">25384335</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kainuma</surname><given-names>M</given-names></name><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Sekiya</surname><given-names>N</given-names></name><name><surname>Tsuneyama</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Takano</surname><given-names>Y</given-names></name><name><surname>Terasawa</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis</article-title><source>Journal of Gastroenterology</source><volume>41</volume><fpage>971</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1007/s00535-006-1883-1</pub-id><pub-id pub-id-type="pmid">17096066</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kangas</surname><given-names>SM</given-names></name><name><surname>Teppo</surname><given-names>J</given-names></name><name><surname>Lahtinen</surname><given-names>MJ</given-names></name><name><surname>Suoranta</surname><given-names>A</given-names></name><name><surname>Ghimire</surname><given-names>B</given-names></name><name><surname>Mattila</surname><given-names>P</given-names></name><name><surname>Uusimaa</surname><given-names>J</given-names></name><name><surname>Varjosalo</surname><given-names>M</given-names></name><name><surname>Katisko</surname><given-names>J</given-names></name><name><surname>Hinttala</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Analysis of human brain tissue derived from DBS surgery</article-title><source>Translational Neurodegeneration</source><volume>11</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1186/s40035-022-00297-y</pub-id><pub-id pub-id-type="pmid">35418104</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klop</surname><given-names>B</given-names></name><name><surname>Elte</surname><given-names>JWF</given-names></name><name><surname>Cabezas</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dyslipidemia in obesity: mechanisms and potential targets</article-title><source>Nutrients</source><volume>5</volume><fpage>1218</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.3390/nu5041218</pub-id><pub-id pub-id-type="pmid">23584084</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Miyashiro</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Kania</surname><given-names>G</given-names></name><name><surname>Błyszczuk</surname><given-names>P</given-names></name><name><surname>Ross</surname><given-names>RL</given-names></name><name><surname>Mulipa</surname><given-names>P</given-names></name><name><surname>Del Galdo</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Distler</surname><given-names>JHW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis</article-title><source>Arthritis Research &amp; Therapy</source><volume>24</volume><elocation-id>210</elocation-id><pub-id pub-id-type="doi">10.1186/s13075-022-02899-3</pub-id><pub-id pub-id-type="pmid">36050717</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotzka</surname><given-names>J</given-names></name><name><surname>Lehr</surname><given-names>S</given-names></name><name><surname>Roth</surname><given-names>G</given-names></name><name><surname>Avci</surname><given-names>H</given-names></name><name><surname>Knebel</surname><given-names>B</given-names></name><name><surname>Muller-Wieland</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Insulin-activated Erk-mitogen-activated protein kinases phosphorylate sterol regulatory element-binding Protein-2 at serine residues 432 and 455 in vivo</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>22404</fpage><lpage>22411</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401198200</pub-id><pub-id pub-id-type="pmid">14988395</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lake</surname><given-names>AD</given-names></name><name><surname>Novak</surname><given-names>P</given-names></name><name><surname>Shipkova</surname><given-names>P</given-names></name><name><surname>Aranibar</surname><given-names>N</given-names></name><name><surname>Robertson</surname><given-names>D</given-names></name><name><surname>Reily</surname><given-names>MD</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Lehman-McKeeman</surname><given-names>LD</given-names></name><name><surname>Cherrington</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease</article-title><source>Toxicology and Applied Pharmacology</source><volume>268</volume><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2013.01.022</pub-id><pub-id pub-id-type="pmid">23391614</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaigre</surname><given-names>FP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Determining the fate of hepatic cells by lineage tracing: facts and pitfalls</article-title><source>Hepatology</source><volume>61</volume><fpage>2100</fpage><lpage>2103</lpage><pub-id pub-id-type="doi">10.1002/hep.27659</pub-id><pub-id pub-id-type="pmid">25503476</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote</article-title><source>Nucleic Acids Research</source><volume>41</volume><elocation-id>e108</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkt214</pub-id><pub-id pub-id-type="pmid">23558742</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>K</given-names></name><name><surname>Tam</surname><given-names>S</given-names></name><name><surname>Murray-Segal</surname><given-names>L</given-names></name><name><surname>Huynh</surname><given-names>K</given-names></name><name><surname>Meikle</surname><given-names>PJ</given-names></name><name><surname>Scott</surname><given-names>JW</given-names></name><name><surname>van Denderen</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Steel</surname><given-names>R</given-names></name><name><surname>LeBlond</surname><given-names>ND</given-names></name><name><surname>Burkovsky</surname><given-names>LA</given-names></name><name><surname>O’Dwyer</surname><given-names>C</given-names></name><name><surname>Nunes</surname><given-names>JRC</given-names></name><name><surname>Steinberg</surname><given-names>GR</given-names></name><name><surname>Fullerton</surname><given-names>MD</given-names></name><name><surname>Galic</surname><given-names>S</given-names></name><name><surname>Kemp</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibition of adenosine monophosphate-activated protein kinase-3-hydroxy-3-methylglutaryl coenzyme a reductase signaling leads to hypercholesterolemia and promotes hepatic steatosis and insulin resistance</article-title><source>Hepatology Communications</source><volume>3</volume><fpage>84</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1002/hep4.1279</pub-id><pub-id pub-id-type="pmid">30619997</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López</surname><given-names>MN</given-names></name><name><surname>Pereda</surname><given-names>C</given-names></name><name><surname>Ramírez</surname><given-names>M</given-names></name><name><surname>Mendoza-Naranjo</surname><given-names>A</given-names></name><name><surname>Serrano</surname><given-names>A</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name><name><surname>Poblete</surname><given-names>R</given-names></name><name><surname>Kalergis</surname><given-names>AM</given-names></name><name><surname>Kiessling</surname><given-names>R</given-names></name><name><surname>Salazar-Onfray</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>48</volume><fpage>1219</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1167/iovs.06-0090</pub-id><pub-id pub-id-type="pmid">17325166</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>IA</given-names></name><name><surname>Triebel</surname><given-names>J</given-names></name><name><surname>Posselt</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Ramadori</surname><given-names>P</given-names></name><name><surname>Raddatz</surname><given-names>D</given-names></name><name><surname>Ramadori</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Melanocortin receptors in rat liver cells: change of gene expression and intracellular localization during acute-phase response</article-title><source>Histochemistry and Cell Biology</source><volume>137</volume><fpage>279</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/s00418-011-0899-7</pub-id><pub-id pub-id-type="pmid">22183812</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manieri</surname><given-names>E</given-names></name><name><surname>Sabio</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Stress kinases in the modulation of metabolism and energy balance</article-title><source>Journal of Molecular Endocrinology</source><volume>55</volume><fpage>R11</fpage><lpage>R22</lpage><pub-id pub-id-type="doi">10.1530/JME-15-0146</pub-id><pub-id pub-id-type="pmid">26363062</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manieri</surname><given-names>E</given-names></name><name><surname>Folgueira</surname><given-names>C</given-names></name><name><surname>Rodríguez</surname><given-names>ME</given-names></name><name><surname>Leiva-Vega</surname><given-names>L</given-names></name><name><surname>Esteban-Lafuente</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Cubero</surname><given-names>FJ</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Cavanagh-Kyros</surname><given-names>J</given-names></name><name><surname>Seruggia</surname><given-names>D</given-names></name><name><surname>Rosell</surname><given-names>A</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Gómez</surname><given-names>MJ</given-names></name><name><surname>Monte</surname><given-names>MJ</given-names></name><name><surname>G Marin</surname><given-names>JJ</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name><name><surname>Mora</surname><given-names>A</given-names></name><name><surname>Sabio</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma</article-title><source>PNAS</source><volume>117</volume><fpage>16492</fpage><lpage>16499</lpage><pub-id pub-id-type="doi">10.1073/pnas.2002672117</pub-id><pub-id pub-id-type="pmid">32601222</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>HK</given-names></name><name><surname>Kapoor</surname><given-names>A</given-names></name><name><surname>Fuchs</surname><given-names>M</given-names></name><name><surname>Mirshahi</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Maher</surname><given-names>J</given-names></name><name><surname>Kellum</surname><given-names>J</given-names></name><name><surname>Warnick</surname><given-names>R</given-names></name><name><surname>Contos</surname><given-names>MJ</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease</article-title><source>Cell Metabolism</source><volume>15</volume><fpage>665</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.04.004</pub-id><pub-id pub-id-type="pmid">22560219</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montero-Melendez</surname><given-names>T</given-names></name><name><surname>Boesen</surname><given-names>T</given-names></name><name><surname>Jonassen</surname><given-names>TEN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics</article-title><source>Seminars in Immunology</source><volume>59</volume><elocation-id>101603</elocation-id><pub-id pub-id-type="doi">10.1016/j.smim.2022.101603</pub-id><pub-id pub-id-type="pmid">35341670</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mountjoy</surname><given-names>KG</given-names></name><name><surname>Robbins</surname><given-names>LS</given-names></name><name><surname>Mortrud</surname><given-names>MT</given-names></name><name><surname>Cone</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The cloning of a family of genes that encode the melanocortin receptors</article-title><source>Science</source><volume>257</volume><fpage>1248</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1126/science.1325670</pub-id><pub-id pub-id-type="pmid">1325670</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mountjoy</surname><given-names>KG</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The human melanocyte stimulating hormone receptor has evolved to become “super-sensitive” to melanocortin peptides</article-title><source>Molecular and Cellular Endocrinology</source><volume>102</volume><fpage>R7</fpage><lpage>R11</lpage><pub-id pub-id-type="doi">10.1016/0303-7207(94)90113-9</pub-id><pub-id pub-id-type="pmid">7926261</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuutinen</surname><given-names>S</given-names></name><name><surname>Ailanen</surname><given-names>L</given-names></name><name><surname>Savontaus</surname><given-names>E</given-names></name><name><surname>Rinne</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Melanocortin overexpression limits diet-induced inflammation and atherosclerosis in LDLR<sup>-/-</sup> mice</article-title><source>The Journal of Endocrinology</source><volume>236</volume><fpage>111</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1530/JOE-17-0636</pub-id><pub-id pub-id-type="pmid">29317531</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandak</surname><given-names>WM</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Marques</surname><given-names>D</given-names></name><name><surname>Hall</surname><given-names>E</given-names></name><name><surname>Redford</surname><given-names>K</given-names></name><name><surname>Mallonee</surname><given-names>D</given-names></name><name><surname>Bohdan</surname><given-names>P</given-names></name><name><surname>Heuman</surname><given-names>D</given-names></name><name><surname>Gil</surname><given-names>G</given-names></name><name><surname>Hylemon</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>48158</fpage><lpage>48164</lpage><pub-id pub-id-type="doi">10.1074/jbc.M205244200</pub-id><pub-id pub-id-type="pmid">12368294</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandak</surname><given-names>WM</given-names></name><name><surname>Kakiyama</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The acidic pathway of bile acid synthesis: Not just an alternative pathway<sup>☆</sup></article-title><source>Liver Research</source><volume>3</volume><fpage>88</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.livres.2019.05.001</pub-id><pub-id pub-id-type="pmid">32015930</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Niswender</surname><given-names>KD</given-names></name><name><surname>Jetton</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Moates</surname><given-names>JM</given-names></name><name><surname>Shelton</surname><given-names>KD</given-names></name><name><surname>Lindner</surname><given-names>J</given-names></name><name><surname>Cherrington</surname><given-names>AD</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using cre recombinase</article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.1.305</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhu</surname><given-names>AV</given-names></name><name><surname>Sharpe</surname><given-names>LJ</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The sterol-based transcriptional control of human 7-dehydrocholesterol reductase (DHCR7): Evidence of a cooperative regulatory program in cholesterol synthesis</article-title><source>Biochimica et Biophysica Acta</source><volume>1842</volume><fpage>1431</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2014.07.006</pub-id><pub-id pub-id-type="pmid">25048193</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pullinger</surname><given-names>CR</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Salen</surname><given-names>G</given-names></name><name><surname>Shefer</surname><given-names>S</given-names></name><name><surname>Batta</surname><given-names>AK</given-names></name><name><surname>Erickson</surname><given-names>SK</given-names></name><name><surname>Verhagen</surname><given-names>A</given-names></name><name><surname>Rivera</surname><given-names>CR</given-names></name><name><surname>Mulvihill</surname><given-names>SJ</given-names></name><name><surname>Malloy</surname><given-names>MJ</given-names></name><name><surname>Kane</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype</article-title><source>The Journal of Clinical Investigation</source><volume>110</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1172/JCI15387</pub-id><pub-id pub-id-type="pmid">12093894</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redding</surname><given-names>TW</given-names></name><name><surname>Kastin</surname><given-names>AJ</given-names></name><name><surname>Nikolics</surname><given-names>K</given-names></name><name><surname>Schally</surname><given-names>AV</given-names></name><name><surname>Coy</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Disapearance and excretion of labeled alpha-MSH in man</article-title><source>Pharmacology, Biochemistry, and Behavior</source><volume>9</volume><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(78)90166-1</pub-id><pub-id pub-id-type="pmid">714971</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichrath</surname><given-names>JJ</given-names></name><name><surname>Girndt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Expression and functional relevance of melatonin receptors in hair follicle biology</article-title><source>Experimental Dermatology</source><volume>14</volume><elocation-id>157</elocation-id><pub-id pub-id-type="doi">10.1111/j.0906-6705.2005.0266p.x</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Hylemon</surname><given-names>PB</given-names></name><name><surname>Marques</surname><given-names>D</given-names></name><name><surname>Gurley</surname><given-names>E</given-names></name><name><surname>Bodhan</surname><given-names>P</given-names></name><name><surname>Hall</surname><given-names>E</given-names></name><name><surname>Redford</surname><given-names>K</given-names></name><name><surname>Gil</surname><given-names>G</given-names></name><name><surname>Pandak</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Overexpression of cholesterol transporter StAR increases in vivo rates of bile acid synthesis in the rat and mouse</article-title><source>Hepatology</source><volume>40</volume><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1002/hep.20382</pub-id><pub-id pub-id-type="pmid">15382124</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinne</surname><given-names>P</given-names></name><name><surname>Ahola-Olli</surname><given-names>A</given-names></name><name><surname>Nuutinen</surname><given-names>S</given-names></name><name><surname>Koskinen</surname><given-names>E</given-names></name><name><surname>Kaipio</surname><given-names>K</given-names></name><name><surname>Eerola</surname><given-names>K</given-names></name><name><surname>Juonala</surname><given-names>M</given-names></name><name><surname>Kähönen</surname><given-names>M</given-names></name><name><surname>Lehtimäki</surname><given-names>T</given-names></name><name><surname>Raitakari</surname><given-names>OT</given-names></name><name><surname>Savontaus</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Deficiency in melanocortin 1 receptor signaling predisposes to vascular endothelial dysfunction and increased arterial stiffness in mice and humans</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>35</volume><fpage>1678</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.305064</pub-id><pub-id pub-id-type="pmid">25931512</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinne</surname><given-names>P</given-names></name><name><surname>Rami</surname><given-names>M</given-names></name><name><surname>Nuutinen</surname><given-names>S</given-names></name><name><surname>Santovito</surname><given-names>D</given-names></name><name><surname>van der Vorst</surname><given-names>EPC</given-names></name><name><surname>Guillamat-Prats</surname><given-names>R</given-names></name><name><surname>Lyytikäinen</surname><given-names>LP</given-names></name><name><surname>Raitoharju</surname><given-names>E</given-names></name><name><surname>Oksala</surname><given-names>N</given-names></name><name><surname>Ring</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>M</given-names></name><name><surname>Hruby</surname><given-names>VJ</given-names></name><name><surname>Lehtimäki</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Steffens</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Melanocortin 1 receptor signaling regulates cholesterol transport in macrophages</article-title><source>Circulation</source><volume>136</volume><fpage>83</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.025889</pub-id><pub-id pub-id-type="pmid">28450348</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinne</surname><given-names>P</given-names></name><name><surname>Kadiri</surname><given-names>JJ</given-names></name><name><surname>Velasco-Delgado</surname><given-names>M</given-names></name><name><surname>Nuutinen</surname><given-names>S</given-names></name><name><surname>Viitala</surname><given-names>M</given-names></name><name><surname>Hollmén</surname><given-names>M</given-names></name><name><surname>Rami</surname><given-names>M</given-names></name><name><surname>Savontaus</surname><given-names>E</given-names></name><name><surname>Steffens</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Melanocortin 1 receptor deficiency promotes atherosclerosis in apolipoprotein E<sup>-/-</sup> Mice</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>38</volume><fpage>313</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.310418</pub-id><pub-id pub-id-type="pmid">29284608</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>AR</given-names></name><name><surname>Almeida</surname><given-names>H</given-names></name><name><surname>Gouveia</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Intracellular signaling mechanisms of the melanocortin receptors: current state of the art</article-title><source>Cellular and Molecular Life Sciences</source><volume>72</volume><fpage>1331</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1007/s00018-014-1800-3</pub-id><pub-id pub-id-type="pmid">25504085</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudman</surname><given-names>D</given-names></name><name><surname>Hollins</surname><given-names>BM</given-names></name><name><surname>Kutner</surname><given-names>MH</given-names></name><name><surname>Moffitt</surname><given-names>SD</given-names></name><name><surname>Lynn</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Three types of alpha-melanocyte-stimulating hormone: bioactivities and half-lives</article-title><source>The American Journal of Physiology</source><volume>245</volume><fpage>E47</fpage><lpage>E54</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.1983.245.1.E47</pub-id><pub-id pub-id-type="pmid">6869528</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Intracellular cholesterol synthesis and transport</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>10</volume><elocation-id>819281</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.819281</pub-id><pub-id pub-id-type="pmid">35386193</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonen</surname><given-names>P</given-names></name><name><surname>Kotronen</surname><given-names>A</given-names></name><name><surname>Hallikainen</surname><given-names>M</given-names></name><name><surname>Sevastianova</surname><given-names>K</given-names></name><name><surname>Makkonen</surname><given-names>J</given-names></name><name><surname>Hakkarainen</surname><given-names>A</given-names></name><name><surname>Lundbom</surname><given-names>N</given-names></name><name><surname>Miettinen</surname><given-names>TA</given-names></name><name><surname>Gylling</surname><given-names>H</given-names></name><name><surname>Yki-Järvinen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity</article-title><source>Journal of Hepatology</source><volume>54</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.05.037</pub-id><pub-id pub-id-type="pmid">20947198</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AI</given-names></name><name><surname>Funder</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues</article-title><source>Endocrine Reviews</source><volume>9</volume><fpage>159</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1210/edrv-9-1-159</pub-id><pub-id pub-id-type="pmid">3286233</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>GR</given-names></name><name><surname>Kemp</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>AMPK in health and disease</article-title><source>Physiological Reviews</source><volume>89</volume><fpage>1025</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1152/physrev.00011.2008</pub-id><pub-id pub-id-type="pmid">19584320</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabibian</surname><given-names>JH</given-names></name><name><surname>Masyuk</surname><given-names>AI</given-names></name><name><surname>Masyuk</surname><given-names>TV</given-names></name><name><surname>O’Hara</surname><given-names>SP</given-names></name><name><surname>LaRusso</surname><given-names>NF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Physiology of cholangiocytes</article-title><source>Comprehensive Physiology</source><volume>3</volume><fpage>541</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1002/cphy.c120019</pub-id><pub-id pub-id-type="pmid">23720296</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeo</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Rabbani</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Lim</surname><given-names>CH</given-names></name><name><surname>Manga</surname><given-names>P</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>EdnrB governs regenerative response of melanocyte stem cells by crosstalk with wnt signaling</article-title><source>Cell Reports</source><volume>15</volume><fpage>1291</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.006</pub-id><pub-id pub-id-type="pmid">27134165</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Than</surname><given-names>NN</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A concise review of non-alcoholic fatty liver disease</article-title><source>Atherosclerosis</source><volume>239</volume><fpage>192</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.01.001</pub-id><pub-id pub-id-type="pmid">25617860</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vernia</surname><given-names>S</given-names></name><name><surname>Cavanagh-Kyros</surname><given-names>J</given-names></name><name><surname>Garcia-Haro</surname><given-names>L</given-names></name><name><surname>Sabio</surname><given-names>G</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shulha</surname><given-names>HP</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway</article-title><source>Cell Metabolism</source><volume>20</volume><fpage>512</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.06.010</pub-id><pub-id pub-id-type="pmid">25043817</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wikberg</surname><given-names>JES</given-names></name><name><surname>Mutulis</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction</article-title><source>Nature Reviews. Drug Discovery</source><volume>7</volume><fpage>307</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1038/nrd2331</pub-id><pub-id pub-id-type="pmid">18323849</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>GSH</given-names></name><name><surname>Chao</surname><given-names>DHM</given-names></name><name><surname>Siegert</surname><given-names>AM</given-names></name><name><surname>Koerperich</surname><given-names>ZM</given-names></name><name><surname>Ericson</surname><given-names>MD</given-names></name><name><surname>Simonds</surname><given-names>SE</given-names></name><name><surname>Larson</surname><given-names>CM</given-names></name><name><surname>Luquet</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>I</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Clément</surname><given-names>K</given-names></name><name><surname>Cowley</surname><given-names>MA</given-names></name><name><surname>Haskell-Luevano</surname><given-names>C</given-names></name><name><surname>Van Der Ploeg</surname><given-names>L</given-names></name><name><surname>Adan</surname><given-names>RAH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The melanocortin pathway and energy homeostasis: From discovery to obesity therapy</article-title><source>Molecular Metabolism</source><volume>48</volume><elocation-id>101206</elocation-id><pub-id pub-id-type="doi">10.1016/j.molmet.2021.101206</pub-id><pub-id pub-id-type="pmid">33684608</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Briggs</surname><given-names>MR</given-names></name><name><surname>Admon</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene</article-title><source>Cell</source><volume>75</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(05)80095-9</pub-id><pub-id pub-id-type="pmid">8402897</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84782.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Quinn</surname><given-names>Matthew A</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Wake Forest School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.11.08.515543" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.11.08.515543"/></front-stub><body><p>The significance of this manuscript is that it provides useful information for the field of hepatology and endocrinology on the regulatory mechanisms of cholesterol homeostasis by melanocortin. The authors provide solid evidence utilizing both in vivo and in vitro molecular, cellular, and biochemical approaches to support their claims.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84782.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Quinn</surname><given-names>Matthew A</given-names></name><role>Reviewing Editor</role><aff><institution>Wake Forest School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Sánchez-Ceinos</surname><given-names>Julia</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056d84691</institution-id><institution>Karolinska Institute</institution></institution-wrap><country>Sweden</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.11.08.515543">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.11.08.515543v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Melanocortin 1 receptor regulates cholesterol and bile acid metabolism in the liver&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Carlos Isales as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Julia Sánchez-Ceinos (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Justify the use of only female mice for in vivo studies.</p><p>2) Colocalization studies by confocal microscopy of MC1-R and different cell type markers (hepatocytes, macrophages, endothelial cells, fibroblasts, cholangiocytes.</p><p>3) Discuss the potential roles of MC1R in cholangiocytes in the modulation of bile acid homeostasis.</p><p>4) Validate hepatic MC1R knockdown at the protein level.</p><p>5) Determine the effects of HFD on disease progression in hepatic MC1R KO mice, or, determine the therapeutic potential of LD211 or MSH in reversing diet-induced obesity.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1) Assess MC1R expression in cholangiocytes via IHC.</p><p>2) Discuss the potential roles of MC1R in cholangiocytes in the modulation of bile acid homeostasis.</p><p>3) Validate hepatic MC1R knockdown at the protein level.</p><p>4) Protein validation for mRNA changes in hepatic genes involved in cholesterol and fatty acid synthesis.</p><p>5) Assess the cholesterol-lowering effect of LD211 in the presence of AMPK inhibitors.</p><p>6) Determine the effects of HFD on disease progression in hepatic MC1R KO mice.</p><p>7) Determine the therapeutic potential of LD211 or MSH in reversing diet-induced obesity.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Below follows specific questions and comments:</p><p>1) Please justify the use of only female mice for in vivo studies.</p><p>2) Although immunohistochemistry images in Figure 1A demonstrating the presence of MC1-R in the liver are convincing and understanding that since hepatocytes represent the more abundant cell type in this organ is plausible to conclude that MC1-R is mainly expressed in these cells, these images do not fully support this conclusion. As mentioned in the introduction (lines 84-87), MC1-R has been also demonstrated to be expressed in a variety of peripheral cells. Therefore, to unequivocally demonstrate that MC1-R is mainly expressed in these cells colocalization studies by confocal microscopy of MC1-R and different cell type markers (hepatocytes, macrophages, endothelial cells, fibroblasts…) are required. Without a robust expression of MC1-R exclusively in hepatocytes, further mechanistic studies are not fully justified.</p><p>3) Concerns regarding the specificity of the antibody used for both immunohistochemistry images in Figure 1A and western blotting analysis in Figure 1C and Supplementary Figure 1 might rise. As a receptor, MC1-R expected localization would be in the plasma membrane whereas on the presented histological images appears to have uniform immunostaining all over the cytoplasm. Likewise, blots in Supplementary Figure 1 show diverse unspecific bands. In this figure, is the lack of bands in HepG2 protein extract due to the species-specificity of the MC1-R antibody? What is the reason behind the use of mouse heart samples in this study?</p><p>4) If experimentally possible and/or publicly available data, expression levels of MC1-R in human liver samples from healthy vs. liver disease (hypercholesterolemia, NASH, NAFLD…) will further strengthen your findings and add valuable translational value to your work.</p><p>5) The observation of that liver from L-MC1-R-/- mice exhibit signs indicative of fibrosis, but no changes were observed in pro-inflammatory genes is intriguing and deserves additional investigation. Does the expression of the fibrosis- and inflammation-related genes tested in the mice changes in the HepG2 under the different treatments employed?</p><p>6) Liquid chromatography-mass spectrometry data from Figure 3 and Supplementary Figures 4 and 5A should be provided as a supplementary table and raw data deposited in an appropriate public data repository with the corresponding mention in the method section. Moreover, a more detailed description of this methodology would be highly appreciated by the readers.</p><p>7) What is the biological relevance of the ratio of CA:CDCA observed in Figure 3G and Supplementary Figure 5B?</p><p>8) The dysregulation of genes involved in bile acid synthesis, uptake/secretion of bile acids, and nuclear receptors in the liver from KO mice is convincing at the mRNA level in Figures 4A-C. At the protein level (Figures 4D and E) it is unclear. Only two of these proteins were confirmed by western blotting studies (and another protein showed contradictory results). These studies are clearly insufficient in order to draw any valid conclusion. The potential changes of a meaningful number of genes should be validated by alternative methods.</p><p>9) Blot images presented in Figures 4D, 5A-C, and 5J, and Supplementary Figures 6C-D and 7E do not seem to have quality enough and/or be representative of their corresponding quantifications. Please replace them in accordance.</p><p>10) The use of HepG2 cells for the in vitro studies is not enough justified. This cellular model is not ideal for the study of metabolic disturbances and does not match some of the criteria used in the in vivo model (they are derived from a male child with hepatocellular carcinoma). It may be understood that they were used for initial screening purposes but selected, key aspects, of the study should be checked in primary hepatocytes from L-MC1-R-/- and control mice.</p><p>11) The decrease in MC1-R in HepG2 in response to palmitic acid, but not when exposed to LDL or atorvastatin, is an interesting observation. Based on what did you choose the selected concentration of these compounds to mimic the cholesterol-rich diet administrated to the animals?</p><p>12) The authors also show that α-MSH treatment reduced the lipid metabolism in hepatocytes. However, it is unclear whether the pathological mechanisms mediated by the downregulation of MC1-R in hepatocytes would be restored by the addition of α-MSH. Additional studies in which MC1-R expression can be manipulated may be needed. Similarly, it would also be worthwhile to use clinically approved melanocortin receptor-targeted drugs in these experiments.</p><p>13) The attempt to elucidate the intracellular signalling cascades that might be behind the beneficial effects of MC1-R in the liver is mostly appreciated. Nevertheless, in the present form, these investigations fail to pinpoint a specific mechanism leading to inconclusive results. It would be more convincing if the authors can perform transcriptomics or proteomics in primary hepatocytes from L-MC1-R-/- and control animals to pursue potential targets.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84782.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Justify the use of only female mice for in vivo studies.</p></disp-quote><p>The use of female mice was based on two main reasons. First, body composition was measured by quantitative NMR scanning, which according to our own experience, can provoke aggressive behavior in group-housed male mice due to cross-contamination of odors (etc. urine) between cages. Second, we had previously observed that pharmacological activation of MC1-R reduced plasma cholesterol level and induced hepatic <italic>Ldlr</italic> expression in female <italic>Apoe<sup>-/-</sup></italic> mice (as discussed on manuscript page 12, lines 475-478), which further supported the preferential use of female mice in the present study.</p><disp-quote content-type="editor-comment"><p>2) Colocalization studies by confocal microscopy of MC1-R and different cell type markers (hepatocytes, macrophages, endothelial cells, fibroblasts, cholangiocytes.</p></disp-quote><p>To obtain a preliminary view on the localization of MC1-R in the liver, we used a publicly available resource (www.livercellatlas.org) to screen for <italic>MC1R</italic> expression in liver single cell RNA-sequencing dataset. Among sequenced nonleukocyte (CD45<sup>-</sup>) cells, <italic>MC1R</italic>-positive cell were mainly hepatocytes but also cholangiocytes, hepatic stellate cells and endothelial cells (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> upper panel). In terms of distribution in myeloid cells, <italic>MC1R</italic>-positive cells were more scarce compared to distribution in CD45<sup>-</sup> cell populations but were spread widely in different monocyte and Kupffer cell (KC) populations (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> lower panel).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-sa2-fig1-v1.tif"/></fig><p>In general, the number of <italic>MC1R</italic>-positve cells was relatively low and probably underestimated due to the low detection sensitivity of scRNA-seq technology and consequent dropout of low-expression genes such as <italic>MC1R</italic>.Nevertheless, the mining of this scRNA-seq dataset gave a good starting point for studying the localization of MC1-R in the mouse liver by double immunofluorescence staining. In line with the expression pattern of <italic>MC1R</italic> in the human liver, the colocalization studies demonstrate the presence of MC1-R in albumin-expressing hepatocytes (Figure 1B). In addition, MC1-R expression colocalized in CK19positive cholangiocytes and Mac2-positive monocytes/macrophages in the mouse liver, but not substantially in CD31-positive endothelial cells (Figure 1—figure supplement 1). These findings open the possibility for investigating the role of MC1R in other cell types of the liver in future studies. Importantly, supporting our initial hypothesis that MC1-R is involved in the regulation of cholesterol and bile acid metabolism in the liver, MC1-R was found to mainly colocalize in hepatocytes and cholangiocytes that are major regulators of cholesterol homeostasis and bile acid synthesis.</p><disp-quote content-type="editor-comment"><p>3) Discuss the potential roles of MC1R in cholangiocytes in the modulation of bile acid homeostasis.</p></disp-quote><p>This is indeed an important aspect of the study, which is supported by the finding of MC1-R expression in cholangiocytes (Figure 1—figure supplement 1). We have now discussed the potential role of MC1-R in this regard (page 12, lines 456462).</p><disp-quote content-type="editor-comment"><p>4) Validate hepatic MC1R knockdown at the protein level.</p></disp-quote><p>As requested, we quantified MC1-R protein expression by Western blotting in the liver of L-Mc1r<sup>-/-</sup> mice. MC1-R protein level was significantly reduced in L-Mc1r<sup>-/-</sup> mice compared to L-Mc1<sup>+/-</sup> mice that were used as controls (Figure 1 figure supplement 3). However, there was considerable residual MC1-R expression in L-Mc1r<sup>-/-</sup> mice, which most likely reflects the presence of MC1-R in nonhepatocytes as discussed above (response to comment #2).</p><disp-quote content-type="editor-comment"><p>5) Determine the effects of HFD on disease progression in hepatic MC1R KO mice, or, determine the therapeutic potential of LD211 or MSH in reversing diet-induced obesity.</p></disp-quote><p>As suggested, we phenotyped the hepatic MC1R KO (L-Mc1r<sup>-/-</sup>) mice after feeding them a cholesterol- and fat-rich Western diet for 12 weeks (RD Western Diet, D12079B, Research Diets Inc, NJ, USA). This was exactly the same dietary regimen (product and duration) that was used to study the changes in hepatic MC1-R expression in wild-type C57Bl mice (Figure 1C and D). We observed that 12-week Western diet feeding induced a significant gain in body weight and total fat mass as well as an increase in plasma and hepatic cholesterol and TG levels (Figure 2—figure supplement 2). L-Mc1r<sup>-/-</sup> mice did not show a difference in body weight gain, but the weight gain was attributable to enhanced gain in fat mass and a blunted increase in lean mass compared to control Mc1r<sup>fl/fl</sup> mice (Figure 2—figure supplement 2A, D and E). Furthermore, liver weight and plasma cholesterol and TG concentrations were unchanged in HFD-fed L-Mc1r<sup>-/-</sup> mice (Figure 2—figure supplement 2B, C, F and G). Importantly, recapitulating the phenotype observed in chow-fed mice, hepatic cholesterol and TG content was significantly increased in L-Mc1r<sup>-/-</sup> mice after a HFD challenge (Figure 2—figure supplement 2H and I). Taken together, it appears that the phenotype of HFD-fed L-Mc1r<sup>-/-</sup> mice was slightly diluted compared to the phenotype observed in chow-fed L-Mc1r<sup>-/-</sup> mice. This phenotypic difference might relate to the finding that Western diet feeding reduced the hepatic expression of MC1-R, thus limiting the incremental effect of genetically induced MC1-R deficiency on hypercholesterolemia and hepatic lipid accumulation.</p><p>We have previously studied the effects of pharmacological MC1-R activation in</p><p>Western diet-fed <italic>Apoe<sup>-/-</sup></italic> mice and observed that chronic treatment with a selective MC1-R agonist reduced plasma cholesterol level and upregulated hepatic <italic>Ldlr</italic> expression without affecting body weight gain (<italic>Rinne P et al., Circulation. 2017 Jul 4;136(1):83-97.</italic>). These findings are also discussed on manuscript page 12/ lines 475478. Although the selective MC1-R agonist was different in that particular study, it is expected that LD211 would also elicit a similar cholesterol-lowering effect in Western diet-fed mice. Chronic treatment with a-MSH, on the other hand, would likely produce wide-ranging metabolic effects. In addition to MC1-R activation in hepatocytes and its consequent effect on liver cholesterol metabolism, a-MSH would affect feeding, energy expenditure and cholesterol metabolism <italic>via</italic> MC4-R activation in the central nervous system as well as fatty acid and glucose metabolism <italic>via</italic> MC5-R activation in the skeletal muscle. Therefore, the phenotype associated with a-MSH treatment would be complex and mediated by multiple mechanisms and MC-R subtypes, thus making it difficult to interpret the exact contribution of hepatic MC1-R signaling to the observed phenotype.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1) Assess MC1R expression in cholangiocytes via IHC.</p></disp-quote><p>As requested, we did a double immunofluorescence staining using MC1-R antibody in combination with an antibody against cytokeratin 19 (CK-19) (<italic>He L et al., Nat. Med. 2017, 23, 1488–1498 and Sekiya S et al., Am J Pathol. 2014 May; 184(5):1468-78</italic>). Figure 1—figure supplement 1 demonstrates the presence of MC1R also in CK19-expressing cholangiocytes.</p><disp-quote content-type="editor-comment"><p>2) Discuss the potential roles of MC1R in cholangiocytes in the modulation of bile acid homeostasis.</p></disp-quote><p>As suggested by the reviewer, we have now discussed the potential role of MC1-R in cholangiocytes (page 12, lines 456-462).</p><disp-quote content-type="editor-comment"><p>3) Validate hepatic MC1R knockdown at the protein level.</p></disp-quote><p>As requested, we quantified MC1-R protein expression by Western blotting in the liver of L-Mc1r<sup>-/-</sup> mice. MC1-R protein level was significantly reduced in L-Mc1r<sup>-/-</sup> mice compared to L-Mc1<sup>+/-</sup> mice that were used as controls (Figure 1figure supplement 3).</p><disp-quote content-type="editor-comment"><p>4) Protein validation for mRNA changes in hepatic genes involved in cholesterol and fatty acid synthesis.</p></disp-quote><p>We quantified the protein expression of SREBP2, HMGCR and DHCR 7 in the liver samples by Western blotting. The results are presented in Figure 2F-H and discussed in more detail above (response to comment 2).</p><disp-quote content-type="editor-comment"><p>5) Assess the cholesterol-lowering effect of LD211 in the presence of AMPK inhibitors.</p></disp-quote><p>As requested, we determined the effect of LD211 on cellular cholesterol level in the presence of the AMPK inhibitor dorsomorphin. Consistently, LD211 significantly reduced cholesterol level in HepG2 cells, while pretreatment of the cells with dorsomorphin completely abolished the cholesterol-lowering effect of LD211 (Figure 7—figure supplement 2).</p><disp-quote content-type="editor-comment"><p>6) Determine the effects of HFD on disease progression in hepatic MC1R KO mice.</p></disp-quote><p>As requested, we fed MC1R KO (L-Mc1r<sup>-/-</sup>) and control a cholesterol- and fat-rich Western diet for 12 weeks (RD Western Diet, D12079B, Research Diets Inc, NJ, USA) and phenotyped them for body weight gain and composition as well as liver and plasma lipid profiles. This was exactly the same dietary regimen (product and duration) that was used to study the changes in hepatic MC1-R expression in wildtype C57Bl mice (Figure 1C and D). We observed that 12-week Western diet feeding induced a significant gain in body weight and total fat mass as well as an increase in plasma and hepatic cholesterol and TG levels (Figure 2—figure supplement 2). LMc1r<sup>-/-</sup> mice did not show a difference in body weight gain, but the weight gain was attributable to enhanced gain in fat mass and a blunted increase in lean mass compared to control mice (Figure 2—figure supplement 2A, D and E). Furthermore, liver weight and plasma cholesterol and TG concentrations were unchanged in HFDfed L-Mc1r<sup>-/-</sup> mice (Figure 2—figure supplement 2B, C, F and G). Importantly, recapitulating the phenotype observed in chow-fed mice, hepatic cholesterol and TG content was significantly increased in L-Mc1r<sup>-/-</sup> mice after a HFD challenge (Figure 2—figure supplement 2H and I). Taken together, it appears that the phenotype of HFDfed L-Mc1r<sup>-/-</sup> mice was slightly diluted compared to the phenotype observed in chowfed L-Mc1r<sup>-/-</sup> mice. This phenotypic difference might relate to the finding that Western diet feeding reduced the hepatic expression of MC1-R, thus limiting the incremental effect of genetically induced MC1-R deficiency on hypercholesterolemia and hepatic lipid accumulation.</p><disp-quote content-type="editor-comment"><p>7) Determine the therapeutic potential of LD211 or MSH in reversing diet-induced obesity.</p></disp-quote><p>We have previously studied the effects of pharmacological MC1-R activation in Western diet-fed mice and observed that chronic treatment with a selective MC1-R agonist reduced plasma cholesterol level and upregulated hepatic <italic>Ldlr</italic> expression without affecting body weight gain (<italic>Rinne P et al., Circulation. 2017 Jul 4;136(1):83-97.</italic>). These findings are also discussed on manuscript page 12/lines 475-479. Although the selective MC1-R agonist was different in that particular study, it is expected that LD211 would also elicit a similar cholesterol-lowering effect in Western diet-fed mice. Chronic treatment with a-MSH, on the other hand, would likely produce wide-ranging metabolic effects. In addition to MC1-R activation in hepatocytes and its consequent effect on liver cholesterol metabolism, a-MSH would affect feeding, energy expenditure and cholesterol metabolism <italic>via</italic> MC4-R activation in the central nervous system as well as fatty acid and glucose metabolism <italic>via</italic> MC5-R activation in the skeletal muscle.</p><p>Therefore, the phenotype associated with a-MSH treatment would be complex and mediated by multiple mechanisms and MC-R subtypes, thus making it difficult to interpret the exact contribution of hepatic MC1-R signaling to the observed phenotype.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Below follows specific questions and comments:</p><p>1) Please justify the use of only female mice for in vivo studies.</p></disp-quote><p>The use of female mice was based on two main reasons. First, body composition was measured by quantitative NMR scanning, which according to our own experience, can provoke aggressive behavior in group-housed male mice due to cross-contamination of odors (etc. urine) between cages. Second, we had previously observed that pharmacological activation of MC1-R reduced plasma cholesterol level and induced hepatic <italic>Ldlr</italic> expression in female <italic>Apoe<sup>-/-</sup></italic> mice (as discussed on manuscript page 12, lines 475-479), which further supported the preferential use of female mice in the present study.</p><disp-quote content-type="editor-comment"><p>2) Although immunohistochemistry images in Figure 1A demonstrating the presence of MC1-R in the liver are convincing and understanding that since hepatocytes represent the more abundant cell type in this organ is plausible to conclude that MC1-R is mainly expressed in these cells, these images do not fully support this conclusion. As mentioned in the introduction (lines 84-87), MC1-R has been also demonstrated to be expressed in a variety of peripheral cells. Therefore, to unequivocally demonstrate that MC1-R is mainly expressed in these cells colocalization studies by confocal microscopy of MC1-R and different cell type markers (hepatocytes, macrophages, endothelial cells, fibroblasts…) are required. Without a robust expression of MC1-R exclusively in hepatocytes, further mechanistic studies are not fully justified.</p></disp-quote><p>Considering that MC1-R is widely expressed in various tissues and cell types, it is very likely that MC1-R is also present in other cell types of the liver besides hepatocytes. Our initial objective was to assess whether MC1-R is expressed in the liver/hepatocytes (and not to specifically investigate its expression in nonhepatocytes). The presence of MC1-R in the liver/hepatocytes gave us the rationale to engineer the hepatocyte-specific MC1-R KO mouse model to investigate the functional significance of MC1-R in the liver. As suggested by the reviewer, we performed double immunofluorescence staining with the MC1-R antibody in combination with antibodies against cell type-specific markers to further investigate the localization of MC1-R in the liver and to validate its presence in hepatocytes. Importantly, these colocalization studies demonstrate the presence of MC1-R in albumin-expressing hepatocytes (Figure 1B). In addition, MC1-R expression colocalized in cholangiocytes and monocytes/macrophages in the mouse liver (Figure 1—figure supplement 1), but not substantially in endothelial cells (Figure 1—figure supplement 1). We do not however understand the reviewer’s comment: ‘Without a robust expression of MC1-R exclusively in hepatocytes, further mechanistic studies are not fully justified’. Why would MC1-R expression in other cell types nullify the justification for studying the role of MC1-R in hepatocytes? As stated in the introduction (page 3, lines 101-108), our hypothesis was based on the previous findings of disturbed cholesterol and bile acid homeostasis in global MC1-R deficient mice. Therefore, we turned our attention to the liver and more specifically to hepatocytes, which are major regulators of cholesterol homeostasis and bile acid synthesis.</p><disp-quote content-type="editor-comment"><p>3) Concerns regarding the specificity of the antibody used for both immunohistochemistry images in Figure 1A and western blotting analysis in Figure 1C and Supplementary Figure 1 might rise. As a receptor, MC1-R expected localization would be in the plasma membrane whereas on the presented histological images appears to have uniform immunostaining all over the cytoplasm. Likewise, blots in Supplementary Figure 1 show diverse unspecific bands. In this figure, is the lack of bands in HepG2 protein extract due to the species-specificity of the MC1-R antibody? What is the reason behind the use of mouse heart samples in this study?</p></disp-quote><p>We thank the reviewer for these remarks. Regarding Figure 1C and Supplementary Figure 1 (Figure 1—figure supplement 2 in the revised submission), the multiple bands on the Western blot most likely represent native, oligomerized and glycosylated forms of MC1-R as have been previously reported and characterized (<italic>Sánchez-Laorden BL et al., J Invest Dermatol. 2006 Jan;126(1):172-81</italic>). Furthermore, all the major bands disappeared in the presence of molar excess of a blocking MC1-R peptide (Figure 1—figure supplement 2), which indicates that the additional bands were not unspecific. The lack of bands in HepG2 cell extracts in this context might be caused by a considerably difference in the expression level of MC-1R between the samples, since the antibody has been tested to react also with human MC1-R. Mouse heart samples were included as a positive control in Supplementary Figure 3, since they are a rich source of endothelial cells, which are known to express MC1-R. Mouse heart samples have been also used in the antibody testing by other companies (<italic>e.g.</italic> https://www.novusbio.com/products/melanocortin-1-r-mc1rantibody_nbp3-02970).</p><p>Regarding the MC1-R immunohistochemistry, it is indeed somewhat unexpected that the positive signal mainly localizes to cytoplasm. However, the appearance of MC1-R positive cells is highly similar with the images provided by the manufacturer (https://www.elabscience.com/p-mc1r_polyclonal_antibody-35168.html) as well as with the images published in other papers (e.g. <italic>Salazar-Onfray F et al., Br J Cancer. 2002 Aug 12;87(4):414-22</italic> and <italic>Cai W at al, Mol Neurodegener. 2022 Feb 23;17(1):16</italic>). It is known that a significant proportion of total MC1-R is internalized and localize to the cytoplasm, particularly in the presence of endogenous/exogenous agonist, which in part explains the expression pattern of MC1-R in the immunohistochemical images.</p><disp-quote content-type="editor-comment"><p>4) If experimentally possible and/or publicly available data, expression levels of MC1-R in human liver samples from healthy vs. liver disease (hypercholesterolemia, NASH, NAFLD…) will further strengthen your findings and add valuable translational value to your work.</p></disp-quote><p>We thank the reviewer for this suggestion, which would indeed add valuable translational value to the study. To this end, we used RNA sequencing data deposited in the Gene Expression Omnibus (GSE120064) to study <italic>MC1R</italic> expression in human liver biopsy samples from patients diagnosed with NAFLD/NASH and from healthy obese control cases (<italic>Govaere O et al., Sci Transl Med. 2020 Dec 2;12(572)</italic>). In good agreement with the findings in Western diet-fed mice, hepatic <italic>MC1R</italic> expression was significantly downregulated.in NAFLD and NASH patients (log2 fold change=-1.1 for both comparisons) (Figure 1E).</p><disp-quote content-type="editor-comment"><p>5) The observation of that liver from L-MC1-R-/- mice exhibit signs indicative of fibrosis, but no changes were observed in pro-inflammatory genes is intriguing and deserves additional investigation. Does the expression of the fibrosis- and inflammation-related genes tested in the mice changes in the HepG2 under the different treatments employed?</p></disp-quote><p>The reviewer raises an important point, which we addressed by analyzing fibrotic and inflammatory gene expression in a-MSH- and LD211-treated HepG2 cells. We found that low concentration (0.1 nM) of LD211 downregulated the expression of fibrotic genes such as <italic>TGFB1</italic>, <italic>ACTA2</italic> and <italic>COL1A1</italic> without affecting the expression of pro-inflammatory genes (Figure 6—figure supplement 1). The concentration-response profile thereby mirrors the changes observed in ERK1/2 and <italic>JNK</italic> phosphorylation (Figure 7B and C, Figure 7—figure supplement 2), which are known to contribute to liver fibrosis (<italic>Jeng K-S et al., Int J Mol Sci. 2020 May 27;21(11):3796</italic> and <italic>Kluwe J et al., Gastroenterology. 2010 Jan;138(1):347-59</italic>). No significant changes were observed in the expression of pro-inflammatory genes. Likewise, low concentration of a-MSH appeared to downregulate the expression of the fibrotic genes <italic>TGFB1</italic> and <italic>COL1A1</italic> (Figure 6—figure supplement 1), but these changes did not reach statistical significance (P=0.08 and 0.051, respectively). These findings suggest that hepatocyte-specific MC1-R deficiency could directly promote liver fibrosis in <italic>L-Mc1r<sup>-/-</sup></italic> mice as discussed on manuscript page 11/lines 413-417.</p><disp-quote content-type="editor-comment"><p>6) Liquid chromatography-mass spectrometry data from Figure 3 and Supplementary Figures 4 and 5A should be provided as a supplementary table and raw data deposited in an appropriate public data repository with the corresponding mention in the method section. Moreover, a more detailed description of this methodology would be highly appreciated by the readers.</p></disp-quote><p>We thank the reviewer for this suggestion and have now provided the liquid chromatography-mass spectrometry data as source data-files. Furthermore, we added a more detailed description of the BA analysis in the ‘Materials and methods’ section (page 16-17, lines 662-723).</p><disp-quote content-type="editor-comment"><p>7) What is the biological relevance of the ratio of CA:CDCA observed in Figure 3G and Supplementary Figure 5B?</p></disp-quote><p>The ratio of CA:CDCA reflects the contribution of the classical and alternative pathways to bile acid synthesis and is largely determined by the enzymatic activity of CYP8B1. Thus, reduced CA:CDCA ratio in L-Mc1r<sup>-/-</sup> mice might indicate compromised CYP8B1 activity as discussed on manuscript page 11/lines 424-437.</p><disp-quote content-type="editor-comment"><p>8) The dysregulation of genes involved in bile acid synthesis, uptake/secretion of bile acids, and nuclear receptors in the liver from KO mice is convincing at the mRNA level in Figures 4A-C. At the protein level (Figures 4D and E) it is unclear. Only two of these proteins were confirmed by western blotting studies (and another protein showed contradictory results). These studies are clearly insufficient in order to draw any valid conclusion. The potential changes of a meaningful number of genes should be validated by alternative methods.</p></disp-quote><p>We thank the reviewer for this suggestion. We aimed to validate those genes at the protein level that could potentially explain the observed BA profile in LMc1r<sup>-/-</sup> mice. It is not uncommon that mRNA level and corresponding protein product of a gene are showing opposite effects. For example, reduced protein level (due to enhanced degradation) could lead to a compensatory increase in mRNA level and the other way around. Therefore, we do not consider the results in Figure 4A and B vs 4D and E to be contradictory, but they rather help to resolve the possible mechanisms leading to disturbed bile acid metabolism in in L-Mc1r<sup>-/-</sup> mice. We acknowledge that the data does not allow making a conclusion on the exact mechanism, but based on the observed reduction in CA:CDCA ratio and changes in CYP8B1 expression, we speculate that MC1-R deficiency primarily disturbs BA synthesis <italic>via</italic> the classical pathways, leading to compensatory changes in the expression of BA transporters and enzymes involved in the alternative BA synthesis pathway. The results are discussed in more detail on manuscript pages 11/lines 428-445.</p><disp-quote content-type="editor-comment"><p>9) Blot images presented in Figures 4D, 5A-C, and 5J, and Supplementary Figures 6C-D and 7E do not seem to have quality enough and/or be representative of their corresponding quantifications. Please replace them in accordance.</p></disp-quote><p>We appreciate the reviewer’s comment and have now replaced the representative blot images as requested. However, based on the low quality of the blot images obtained with phospho-Akt and total Akt antibodies, we decided to exclude the Supplementary Figures 6D-E and 7E (Figure 7—figure supplement 1 and Figure 7figure supplement 2 in the revised manuscript). This does not affect the conclusions of the manuscript because the underlying mechanisms appear to be independent of Akt phosphorylation.</p><disp-quote content-type="editor-comment"><p>10) The use of HepG2 cells for the in vitro studies is not enough justified. This cellular model is not ideal for the study of metabolic disturbances and does not match some of the criteria used in the in vivo model (they are derived from a male child with hepatocellular carcinoma). It may be understood that they were used for initial screening purposes but selected, key aspects, of the study should be checked in primary hepatocytes from L-MC1-R-/- and control mice.</p></disp-quote><p>We agree with the reviewer that HepG2 cells are not an ideal in vitro model to study certain aspects of hepatocyte biology. Despite the apparent differences between HepG2 cells and primary hepatocytes, comparative studies have demonstrated that these models have similar properties in terms of cholesterol metabolism (<italic>Nagarajan SR et al., Am J Physiol Endocrinol Metab. 2019 Apr 1;316(4):E578-E589</italic> and <italic>Wang SR et al., Biochim Biophys Acta. 1988 Aug 12;961(3):351-63</italic>). More importantly, the central model of the study is the hepatocyte-specific MC1-R deficient mice that were used to test the hypothesis that MC1-R is expressed in hepatocytes and involved in the regulation of cholesterol metabolism. Having noted a phenotype of enhanced lipid accumulation in L-Mc1r<sup>-/-</sup> mice, we proceeded to investigate the direct actions and underlying mechanisms of aMSH and the selective MC1-R agonist in HepG2 cells. Without the in vivo evidence, it would be more critical to investigate whether the key responses observed in HepG2 cells are also recapitulated in primary hepatocytes.</p><p>We originally planned to address the reviewer’s comment by isolating primary hepatocytes from <italic>L-Mc1r<sup>-/-</sup></italic> and control mice. However, after producing new mice for the in vivo experiment (Figure 2—figure supplement 2), we have had major difficulties in expanding and even maintaining this mouse colony. Therefore, we have not been able to perform these experiments within a reasonable time frame.</p><disp-quote content-type="editor-comment"><p>11) The decrease in MC1-R in HepG2 in response to palmitic acid, but not when exposed to LDL or atorvastatin, is an interesting observation. Based on what did you choose the selected concentration of these compounds to mimic the cholesterol-rich diet administrated to the animals?</p></disp-quote><p>The concentrations of palmitic acid, LDL and atorvastatin were selected based on previous publications that have demonstrated these concentrations to evoke significant biological responses in terms of lipid and cholesterol loading (<italic>Hae Seo M et al., PLoS One. 2016 Dec 1;11(12)</italic> and <italic>Feng J et al., Commun Biol. 2019 May 8;2:173.</italic>) and cholesterol depletion (<italic>e.g. Mohammadi A et al., Arterioscler Thromb Vasc Biol. 1998 May;18(5):783-93</italic>.), respectively. The purpose was not to specifically mimic the cholesterol-rich diet administered to the animals, because it is highly challenging to estimate the exposure of hepatocytes in vivo to different components of the diet. Furthermore, even if the exposure could be estimated, HepG2 cells might respond to the treatments at a different concentration compared to primary hepatocytes.</p><disp-quote content-type="editor-comment"><p>12) The authors also show that α-MSH treatment reduced the lipid metabolism in hepatocytes. However, it is unclear whether the pathological mechanisms mediated by the downregulation of MC1-R in hepatocytes would be restored by the addition of α-MSH. Additional studies in which MC1-R expression can be manipulated may be needed. Similarly, it would also be worthwhile to use clinically approved melanocortin receptor-targeted drugs in these experiments.</p></disp-quote><p>We thank the reviewer for these suggestions. We do not however understand what the reviewer means by ‘<italic>it is unclear whether the pathological mechanisms mediated by the downregulation of MC1-R in hepatocytes would be restored by the addition of</italic> a<italic>-MSH</italic>.’ MC1-R deficiency/downregulation in hepatocytes is likely to disturb the signaling mediated by the endogenous MC1-R agonist a-MSH as well as to lead to pathological changes even in the absence of aMSH, considering that MC1-R possesses agonist-independent constitutive activity (<italic>e.g. Sánchez-Más J et al., Pigment Cell Res. 2004 Aug;17(4):386-95</italic>). The addition of a-MSH to a MC1-R deficient model is likely to evoke signaling <italic>via</italic> other MC-R subtypes (and MC1-R in other tissues/cell types) and could thus potentially restore some pathophysiological mechanisms caused by hepatocyte-specific MC1-R deficiency/MC1-R downregulation. We do not however anticipate that addition of aMSH would restore MC1-R expression/activity in hepatocytes and therefore, this kind of experiment would not help in unraveling the role of MC1-R signaling in hepatocytes. Likewise, the use of clinically approved melanocortin receptor-targeted drugs in these experiments would involve significant uncertainty in evaluating the contribution of MC1-R-dependent signaling on the observed effects, since none of these drugs is selective for MC1-R.</p><disp-quote content-type="editor-comment"><p>13) The attempt to elucidate the intracellular signalling cascades that might be behind the beneficial effects of MC1-R in the liver is mostly appreciated. Nevertheless, in the present form, these investigations fail to pinpoint a specific mechanism leading to inconclusive results. It would be more convincing if the authors can perform transcriptomics or proteomics in primary hepatocytes from L-MC1-R-/- and control animals to pursue potential targets.</p></disp-quote><p>As suggested by the reviewer, we performed transcriptomics/RNA sequencing analysis for liver samples from L-Mc1r<sup>-/-</sup> and control mice. Unfortunately, we did not have sufficient number of mice with desired genotypes to be used for primary hepatocyte isolation and subsequent transcriptomics. Thus, we needed to perform transcriptomics using previously collected liver samples. A Volcano plot of differentially expressed genes (DEGs) in the liver of chow-fed L-Mc1r<sup>-/-</sup> (n=4) versus L-Mc1r<sup>+/-</sup> mice (n=4) is shown in <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>. The x-axis shows log2 fold changes (logFC) between genotypes, the y-axis plots negative log10 P-values.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-sa2-fig2-v1.tif"/></fig><p>Among the most significant DEGs, apolipoprotein A-IV (<italic>Apoa4</italic>) and sortilin-related receptor, LDLR class A (<italic>Sorl1</italic>) were upregulated (FDR-corrected P&lt;0.0001) in the liver of chow-fed L-Mc1r<sup>-/-</sup> mice. These DEGs were also validated by qPCR (<xref ref-type="fig" rid="sa2fig3">Author response image 3</xref>).</p><fig id="sa2fig3" position="float"><label>Author response image 3.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84782-sa2-fig3-v1.tif"/></fig><p><italic>Apoa4</italic> gene is known to be expressed in the intestine and implicated in lipid absorption. In rodents, <italic>Apoa4</italic> is also expressed in the liver and robustly upregulated after experimentally induced hepatic steatosis (<italic>VerHague MA et al., Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2501-8</italic>). Therefore, the upregulation of <italic>Apoa4</italic> in <italic>L-Mc1r<sup>-/-</sup></italic> mice might be a consequence rather than driver of increased lipid accumulation in the liver. <italic>Sorl1</italic>, on the other hand, has been implicated in the pathogenesis of Alzheimer’s disease, but also in metabolic regulation. Overexpression of <italic>Sorl1</italic> in adipocytes inhibits release of free fatty acids and enhances fat deposition (<italic>Schmidt V et al., J Clin Invest. 2016 Jul 1;126(7):2706-20</italic>). However, the role of <italic>Sorl1</italic> in the liver is unknown. In addition, gene set enrichment analysis (GSEA) for gene ontology revealed only one significant term: extracellular space (adjusted Pvalue: 0.0071, number of genes: 55).Taken together, the results of RNA-seq analysis do not provide clear answers that would help in identifying potential targets that could explain the observed phenotype in L-Mc1r<sup>-/-</sup> mice. Therefore, we would rather omit these data from the main manuscript.</p></body></sub-article></article>